Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023.


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 1-07151

THE CLOROX COMPANY

(Exact name of registrant as specified in its charter)


Delaware			31-0595760
(State or other jurisdiction of			(I.R.S. Employer Identification No.)
incorporation or organization)

1221 Broadway, Oakland, California, 94612-1888

(Address of principal executive offices) (Zip code)

(510) 271-7000

(Registrant’s telephone number, including area code)


(Former name, former address and former fiscal year, if changed since last report)
___________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock - $1.00 par value	CLX	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☑

Accelerated filer

☐

Non-accelerated filer

☐

Smaller Reporting Company

☐

Emerging Growth Company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

As of October 18, 2023, there were 124,059,098 shares outstanding of the registrant’s common stock ($1.00 par value).

TABLE OF CONTENTS


						Page
PART I - FINANCIAL INFORMATION						3
I tem 1. Financial Statements						3
Condensed Consolidated Statements of Earnings and Comprehensive Income						3
Condensed Consolidated Balance Sheets						4
C ondensed Consolidated Statements of Cash Flows						5
N otes to Condensed Consolidated Financial Statements						6
I tem 2. Man agement ’s Discussion and Analysis of Financial Condition and Results of Operations						18
I tem 3. Quantitative and Qualitative Disclosures About Market Risk						30
I tem 4. Controls and Procedures						30
PART II - OTHER INFORMATION						31
I tem 1.A. Risk Factors						31
I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds						33
I tem 5. Other Information						33
I tem 6. Exhibits						34

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

The Clorox Company

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)

(Dollars in millions, except per share data)


	Three months ended
	9/30/2023		9/30/2022
Net sales	$	1,386	$	1,740
Cost of products sold		854		1,114
Gross profit		532		626
Selling and administrative expenses		276		261
Advertising costs		165		161
Research and development costs		29		32

Interest expense		21		22
Other (income) expense, net		12		34
Earnings before income taxes		29		116
Income tax expense		4		29
Net earnings		25		87
Less: Net earnings attributable to noncontrolling interests		3		2
Net earnings attributable to Clorox	$	22	$	85
Net earnings per share attributable to Clorox
Basic net earnings per share	$	0.17	$	0.69
Diluted net earnings per share	$	0.17	$	0.68
Weighted average shares outstanding (in thousands)
Basic		123,973		123,339
Diluted		124,650		123,914

Comprehensive income	$	24	$	51
Less: Total comprehensive income attributable to noncontrolling interests		3		2
Total comprehensive income attributable to Clorox	$	21	$	49

See Notes to Condensed Consolidated Financial Statements (Unaudited)

The Clorox Company

Condensed Consolidated Balance Sheets

(Dollars in millions, except per share data)


	9/30/2023		6/30/2023
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	518	$	367
Receivables, net		581		688
Inventories, net		710		696
Prepaid expenses and other current assets		102		77
Total current assets		1,911		1,828
Property, plant and equipment, net of accumulated depreciation and amortization of $2,768 and $2,705, respectively		1,317		1,345
Operating lease right-of-use assets		328		346
Goodwill		1,246		1,252
Trademarks, net		541		543
Other intangible assets, net		162		169
Other assets		486		462
Total assets	$	5,991	$	5,945
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Notes and loans payable	$	347	$	50

Current operating lease liabilities		88		87
Accounts payable and accrued liabilities		1,678		1,659
Income taxes payable		115		121
Total current liabilities		2,228		1,917
Long-term debt		2,478		2,477
Long-term operating lease liabilities		290		310
Other liabilities		837		825
Deferred income taxes		27		28
Total liabilities		5,860		5,557
Commitments and contingencies
Stockholders’ equity
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding		—		—
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of September 30, 2023 and June 30, 2023; and 124,001,348 and 123,820,022 shares outstanding as of September 30, 2023 and June 30, 2023, respectively		131		131
Additional paid-in capital		1,246		1,245
Retained earnings		299		583
Treasury stock, at cost: 6,740,113 and 6,921,439 shares as of September 30, 2023 and June 30, 2023, respectively		(1,219)		(1,246)
Accumulated other comprehensive net (loss) income		(494)		(493)
Total Clorox stockholders’ (deficit) equity		(37)		220
Noncontrolling interests		168		168
Total stockholders’ equity		131		388
Total liabilities and stockholders’ equity	$	5,991	$	5,945

See Notes to Condensed Consolidated Financial Statements (Unaudited)

The Clorox Company

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in millions)


	Three months ended
	9/30/2023		9/30/2022
Operating activities:
Net earnings	$	25	$	87
Adjustments to reconcile net earnings to net cash provided by operations:
Depreciation and amortization		61		56
Stock-based compensation		13		10
Deferred income taxes		(5)		(5)

Other		1		16
Changes in:
Receivables, net		108		63
Inventories, net		(14)		(6)
Prepaid expenses and other current assets		(22)		(30)
Accounts payable and accrued liabilities		(138)		(28)
Operating lease right-of-use assets and liabilities, net		(1)		1
Income taxes payable / prepaid		(8)		14
Net cash provided by operations		20		178
Investing activities:
Capital expenditures		(24)		(46)

Other		1		1
Net cash used for investing activities		(23)		(45)
Financing activities:
Notes and loans payable, net		298		111


Cash dividends paid to Clorox stockholders		(149)		(145)

Issuance of common stock for employee stock plans and other		6		(1)
Net cash provided by (used for) financing activities		155		(35)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		—		(4)
Net increase (decrease) in cash, cash equivalents and restricted cash		152		94
Cash, cash equivalents and restricted cash:
Beginning of period		368		186
End of period	$	520	$	280

See Notes to Condensed Consolidated Financial Statements (Unaudited)

The Clorox Company

Notes to Condensed Consolidated Financial Statements (Unaudited)

(Dollars in millions, except per share data)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2023 and 2022, in the opinion of management, reflect all normal and recurring adjustments considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company or Clorox) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2023, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Recently Adopted Accounting Standards

In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the condensed consolidated financial statements, results of operations, or cash flows.

NOTE 2. CYBERATTACK

On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its Information Technology (IT) systems. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the quarter.

The impacts of these system disruptions included order processing delays and significant product outages, resulting in a negative impact on net sales and earnings. The Company has since transitioned back to automated order processing and the vast majority of orders are taking place in an automated manner. The Company expects to experience ongoing, but lessening, operational impacts in the second quarter as it makes progress in returning to normalized operations.

The Company also incurred incremental expenses of approximately $24 as a result of the cyberattack for the three months ended September 30, 2023. The following table summarizes the recognition of costs in the condensed consolidated statement of earnings and comprehensive income:


	Three months ended
	9/30/2023
Costs of products sold	$	11
Selling and administrative expenses	13
Total	$	24

The costs incurred relate primarily to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs incurred from the resulting disruption to the Company’s business operations. The Company expects to incur additional costs related to the

NOTE 2. CYBERATTACK (Continued)

cyberattack in future periods. The Company has not recognized any insurance proceeds in the three months ended September 30, 2023 related to the cyberattack. The timing of recognizing insurance recoveries, if any, may differ from the timing of recognizing the associated expenses.

NOTE 3. SUPPLY CHAIN FINANCING PROGRAM

The Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier by selling the Company’s payables to the financial institution. Participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets, cash flows or liquidity. The Company and our subsidiaries have not pledged any assets as security or provided guarantees under the SCF program.

All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable and accrued liabilities in the condensed consolidated balance sheets and the associated payments are included in operating activities within the condensed consolidated statements of cash flows. As of September 30, 2023 and June 30, 2023, the amount due to suppliers participating in the SCF program and included in Accounts payable and accrued liabilities was $119 and $220, respectively. The decrease in the amount due to suppliers participating in the SCF program from June 30, 2023 to September 30, 2023 was attributable to a reduction of orders due to the temporary operational disruptions of the cyberattack along with the timing of payments.

NOTE 4. RESTRUCTURING AND RELATED COSTS

In the first quarter of fiscal year 2023, the Company began recognizing costs related to a plan that involves streamlining its operating model to meet its objectives of driving growth and productivity. The streamlined operating model is expected to enhance the Company’s ability to respond more quickly to changing consumer behaviors and innovate faster. The Company anticipates the implementation of this new model will be completed in fiscal year 2024, with different phases occurring throughout the implementation period.

The Company incurred $60 of costs in fiscal year 2023 and anticipates incurring approximately $30 to $40 of costs in fiscal year 2024 related to this initiative, of which approximately $10 to $15 are expected to be employee-related costs to reduce certain staffing levels such as severance payments, with the remainder for consulting and other costs. Costs incurred are expected to be settled primarily in cash.

The total restructuring and related implementation costs, net associated with the Company’s streamlined operating model plan as reflected in the condensed consolidated statements of earnings and comprehensive income:


	Three months ended				Inception to date ended
	9/30/2023		9/30/2022			9/30/2023
Costs of products sold	$	—	$	(1)		$	(3)
Selling and administrative expenses	—		1			12
Research and development	—		—			(1)
Other (income) expense, net:
Employee-related costs	—		19			52


Total, net	$	—	$	19		$	60

Employee-related costs primarily include severance and other termination benefits calculated based on salary levels, prior service and statutory requirements. Other costs primarily include consulting fees incurred for the organizational design and implementation of the streamlined operating model, related processes and other professional fees incurred.

The Company may, from time to time, decide to pursue additional restructuring-related initiatives that involve costs in future periods.

NOTE 4. RESTRUCTURING AND RELATED COSTS (Continued)

The following table reconciles the accrual for the streamlined operating model’s restructuring and related implementation costs discussed above, which are recorded within Accounts payable and accrued liabilities in the condensed consolidated balance sheets:


	Employee-Related Costs		Other		Total
Accrual Balance as of June 30, 2023	$	23	$	5	$	28
Charges	—		—		—
Cash payments	(16)		(5)		(21)

Accrual Balance as of September 30, 2023	$	7	$	—	$	7

NOTE 5. INVENTORIES, NET

Inventories, net consisted of the following as of:


	9/30/2023		6/30/2023
Finished goods	$	618	$	595
Raw materials and packaging	178		182
Work in process	20		8
LIFO allowances	(104)		(87)
Total inventories, net	$	712	$	698
Less: Non-current inventories, net (1)	2		2
Total current inventories, net	$	710	$	696

(1)Non-current inventories, net are recorded in Other assets.

NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity futures, options and swap contracts to limit the impact of price volatility on a portion of its forecasted raw material requirements. These commodity derivatives may be exchange traded or over-the-counter contracts and generally have original contractual maturities of less than 2 years. Commodity purchase and options contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of September 30, 2023, and June 30, 2023, the notional amount of commodity derivatives was $36 and $41, respectively, which related primarily to exposures in soybean oil used for the Food business and jet fuel used for the Grilling business.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have original contractual maturities of less than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $55 and $51 as of September 30, 2023 and June 30, 2023, respectively.

Interest Rate Risk Management

NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have original contractual maturities of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.

The Company held no interest rate contracts as of both September 30, 2023 and June 30, 2023.

Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward, futures and options contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges.

The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:


	Gains (losses) recognized in Other comprehensive (loss) income
	Three months ended
	9/30/2023		9/30/2022
Commodity purchase derivative contracts	$	(1)	$	(3)
Foreign exchange derivative contracts	1		1
Interest rate derivative contracts	—		—
Total	$	—	$	(2)


	Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings	Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
		Three months ended
		9/30/2023		9/30/2022
Commodity purchase derivative contracts	Cost of products sold	$	(2)	$	4
Foreign exchange derivative contracts	Cost of products sold	—		1
Interest rate derivative contracts	Interest expense	3		3
Total		$	1	$	8

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of September 30, 2023 that is expected to be reclassified into Net earnings within the next twelve months is $13.

Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions, $0 and $1 contained such terms as of September 30, 2023 and June 30, 2023, respectively. As of both September 30, 2023 and June 30, 2023, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the Company’s credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both September 30, 2023 and June 30, 2023, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange traded futures and options contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of September 30, 2023 and June 30, 2023, the Company maintained cash margin balances

NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

related to exchange traded futures and options contracts of $2 and $0, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.

Trust Assets

The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and therefore trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The gains and losses on the trust assets are recorded in Other (income) expense, net in the condensed consolidated statements of earnings. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value of Financial Instruments

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of both September 30, 2023 and June 30, 2023, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.

All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:


			9/30/2023				6/30/2023
	Balance sheet classification	Fair value hierarchy level	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets
Commodity purchase options contracts	Prepaid expenses and other current assets	1	$	—	$	—	$	2	$	2
Commodity purchase swaps contracts	Prepaid expenses and other current assets	2	1		1		—		—

Foreign exchange forward contracts	Prepaid expenses and other current assets	2	2		2		—		—

			$	3	$	3	$	2	$	2
Liabilities
Commodity purchase futures contracts	Accounts payable and accrued liabilities	1	1		1		—		—
Commodity purchase swaps contracts	Accounts payable and accrued liabilities	2	—		—		1		1

			$	1	$	1	$	1	$	1

NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:


			9/30/2023				6/30/2023
	Balance sheet classification	Fair value hierarchy level	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets
Interest-bearing investments, including money market funds	Cash and cash equivalents (1)	1	$	388	$	388	$	243	$	243
Time deposits	Cash and cash equivalents (1)	2	16		16		9		9


Trust assets for nonqualified deferred compensation plans	Other assets	1	137		137		129		129
			$	541	$	541	$	381	$	381
Liabilities
Notes and loans payable	Notes and loans payable (2)	2	$	347	$	347	$	50	$	50

Current maturities of long-term debt and Long-term debt	Current maturities of long- term debt and Long-term debt (3)	2	2,478		2,259		2,477		2,327
			$	2,825	$	2,606	$	2,527	$	2,377

(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.

(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances and/or amounts drawn on the Company’s credit agreements, all of which are recorded at cost, which approximates fair value.

(3)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.

NOTE 7. INCOME TAXES

In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 14.6% and 25.0% for the three months ended September 30, 2023 and 2022, respectively. The lower tax rate on earnings was primarily driven by the impact of temporary relief provided by the Internal Revenue Service relating to U.S. foreign tax credit regulations.

NOTE 8. NET EARNINGS PER SHARE (EPS)

The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:


	Three months ended
	9/30/2023	9/30/2022
Basic	123,973	123,339
Dilutive effect of stock options and other	677	575
Diluted	124,650	123,914

Antidilutive stock options and other	2,220	2,983

Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.

NOTE 9. COMPREHENSIVE INCOME

The following table provides a summary of Comprehensive income for the periods indicated:


	Three months ended
	9/30/2023		9/30/2022
Net earnings	$	25	$	87
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(11)		(29)
Net unrealized gains (losses) on derivatives	(1)		(8)
Pension and postretirement benefit adjustments	11		1
Total other comprehensive (loss) income, net of tax	(1)		(36)
Comprehensive income	24		51
Less: Total comprehensive income attributable to noncontrolling interests	3		2
Total comprehensive income attributable to Clorox	$	21	$	49

NOTE 10. STOCKHOLDERS’ EQUITY

Changes in the components of Stockholders’ equity were as follows for the periods indicated:


	Three months ended September 30
(Dollars in millions except per share data; shares in thousands)	Common stock			Additional paid-in capital		Retained earnings		Treasury stock			Accumulated other comprehensive net (loss) income		Noncontrolling interests		Total stockholders’ equity
	Amount		Shares					Amount		Shares
Balance as of June 30, 2022	$	131	130,741	$	1,202	$	1,048	$	(1,346)	(7,589)	$	(479)	$	173	$	729
Net earnings	—		—	—		85		—		—	—		2		87
Other comprehensive (loss) income	—		—	—		—		—		—	(36)		—		(36)
Dividends to Clorox stockholders ($2.36 per share declared)	—		—	—		(293)		—		—	—		—		(293)
Dividends to noncontrolling interests	—		—	—		—		—		—	—		(5)		(5)

Stock-based compensation	—		—	10		—		—		—	—		—		10
Other employee stock plan activities	—		—	(19)		(8)		31		204	—		—		4


Balance as of September 30, 2022	$	131	130,741	$	1,193	$	832	$	(1,315)	(7,385)	$	(515)	$	170	$	496

Balance as of June 30, 2023	$	131	130,741	$	1,245	$	583	$	(1,246)	(6,921)	$	(493)	$	168	$	388
Net earnings (losses)	—		—	—		22		—		—	—		3		25
Other comprehensive (loss) income	—		—	—		—		—		—	(1)		—		(1)
Dividends to Clorox stockholders ($2.40 per share declared)	—		—	—		(300)		—		—	—		—		(300)
Dividends to noncontrolling interests	—		—	—		—		—		—	—		(3)		(3)

Stock-based compensation	—		—	13		—		—		—	—		—		13
Other employee stock plan activities	—		—	(12)		(6)		27		181	—		—		9



Balance as of September 30, 2023	$	131	130,741	$	1,246	$	299	$	(1,219)	(6,740)	$	(494)	$	168	$	131

NOTE 10. STOCKHOLDERS’ EQUITY (Continued)

Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:


	Three months ended September 30
	Foreign currency translation adjustments		Net unrealized gains (losses) on derivatives		Pension and postretirement benefit adjustments		Accumulated other comprehensive net (loss) income
Balance as of June 30, 2022	$	(448)	$	121	$	(152)	$	(479)
Other comprehensive (loss) income before reclassifications	(29)		(2)		—		(31)
Amounts reclassified from Accumulated other comprehensive net (loss) income	—		(8)		1		(7)
Income tax benefit (expense)	—		2		—		2
Net current period other comprehensive (loss) income	(29)		(8)		1		(36)
Balance as of September 30, 2022	$	(477)	$	113	$	(151)	$	(515)

Balance as of June 30, 2023	$	(445)	$	99	$	(147)	$	(493)
Other comprehensive (loss) income before reclassifications	(11)		—		11		—
Amounts reclassified from Accumulated other comprehensive net (loss) income	—		(1)		3		2
Income tax benefit (expense), and other	—		—		(3)		(3)
Net current period other comprehensive (loss) income	(11)		(1)		11		(1)
Balance as of September 30, 2023	$	(456)	$	98	$	(136)	$	(494)

NOTE 11. EMPLOYEE BENEFIT PLANS

The Company has a domestic qualified pension plan (the Plan). The Plan is frozen for all participants. The Plan generally was frozen effective June 30, 2011 for all employees, except for certain collectively bargained employees, whose Plan freeze was effective January 1, 2019. As a result of the Plan freeze, no employees are eligible to commence participation in the Plan or accrue any additional benefits under the Plan.

On May 17, 2022, the Company’s Board of Directors approved a resolution to terminate the Plan. The amendment will allow the settlement of the pension obligation with either a lump sum payout or a purchased annuity. The Plan is fully funded under specified Employee Retirement Income Security Act (ERISA) funding rules as of September 30, 2023.

In anticipation of this settlement, the Company remeasured the plan’s benefit obligation as of September 30, 2023, based on a discount rate of 5.0% which resulted in a net unrealized loss balance of $126, net of tax, ($165 before taxes) in Accumulated other comprehensive net (loss) income on its condensed consolidated balance sheet related to the Plan.

In the second quarter of fiscal year 2024, a one-time non-cash settlement charge of approximately $165 (before taxes) is expected to be recognized in the Company’s condensed consolidated statement of earnings and comprehensive income, related to these net unrealized losses, as plan obligations are settled through both lump sum payouts and annuity purchases. The actual amount of the settlement charge could vary based on the final valuation of assets and liabilities. On October 10, 2023, the Company completed the annuity purchase related to the pension plan termination. On October 31, 2023, the Company paid out the lump sum amounts related to the termination.

NOTE 11. EMPLOYEE BENEFIT PLANS (Continued)

The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:


	Three months ended
	9/30/2023		9/30/2022

Interest cost	$	5	$	5
Expected return on plan assets (1)	(3)		(3)
Settlement loss recognized	1		—
Amortization of unrecognized items	2		2
Total	$	5	$	4

(1)The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2024 net periodic benefit cost is 3.5%.

The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2023 and 2022.

During both the three months ended September 30, 2023 and 2022, the Company made $2 in contributions to its domestic retirement income plans.

Service cost component of the net periodic benefit cost, if any, is reflected in employee benefit costs. All other components are reflected in Other (income) expense, net.

NOTE 12. OTHER CONTINGENCIES AND GUARANTEES

Contingencies

The Company is involved in certain environmental matters, including response actions at various locations. The Company recorded liabilities totaling $28 as of both September 30, 2023 and June 30, 2023, respectively, for its share of aggregate future remediation costs related to these matters.

One matter, which accounted for $12 of the recorded liability as of both September 30, 2023 and June 30, 2023, respectively, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing groundwater at the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study related to groundwater. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators. In January 2023, the regulators issued a new order directing the Company and the current property owner to conduct a Remedial Investigation and then prepare a Feasibility Study to evaluate and remediate impacts to soil, soil vapor and indoor air. While the Company believes its latest estimates of remediation costs (including any related to soil, soil vapor and indoor air impacts) are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs in the aggregate of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs.

Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability as of both September 30, 2023 and June 30, 2023, respectively. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing agreement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time.

The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. From time to time, the Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements (including costs connected to the transition and unwinding of certain supply and manufacturing relationships), product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings,

NOTE 12: OTHER CONTINGENCIES AND GUARANTEES (continued)

claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.

Guarantees

In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.

The Company had not recorded any material liabilities on the aforementioned guarantees as of both September 30, 2023 and June 30, 2023.

The Company was a party to letters of credit of $15 as of September 30, 2023, primarily related to its insurance carriers, of which $0 had been drawn upon.

NOTE 13. SEGMENT RESULTS

The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other.

Corporate and Other includes certain non-allocated administrative costs and various other non-operating income and expenses, as well as the results of the Vitamins, Minerals and Supplements (VMS) business. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes, as well as the assets related to the VMS business.

The principle measure of segment profitability used by management is segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT). Segment adjusted EBIT is defined as earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as charges relating to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions and other nonrecurring or unusual items impacting comparability).

The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate and Other.

NOTE 13. SEGMENT RESULTS (Continued)


	Net sales
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	504	$	657
Household	325		423
Lifestyle	229		320
International	270		285
Corporate and Other	58		55

Total	$	1,386	$	1,740

	Segment adjusted EBIT
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	104	$	133
Household	(4)		22
Lifestyle	19		60
International	34		23
Corporate and Other	(62)		(63)
Total	$	91	$	175
Interest income	10		2
Interest expense	(21)		(22)

Cyberattack costs (1)	(24)		—
Streamlined operating model (2)	—		(19)
Digital capabilities and productivity enhancements investment (3)	(27)		(20)
Earnings before income taxes	$	29	$	116

(1)Represents incremental costs related to the cyberattack detailed in Note 2. For informational purposes the following table provides the approximate cyberattack costs corresponding to the Company’s reportable segments as a percentage of total costs:


	Three months ended
	9/30/2023
Health and Wellness	22	%
Household	11
Lifestyle	14
International	1
Corporate and Other	52
Total	100	%

(2)Represents restructuring and related implementation costs, net for the streamlined operating model of $0 and $19 for the three months ended September 30, 2023 and 2022, respectively. For informational purposes the following table provides the approximate restructuring and related implementation costs, net corresponding to the Company’s reportable segments as a percentage of the total costs:


	Three months ended		Three months ended		Inception to date ended
	9/30/2023		9/30/2022		9/30/2023
Health and Wellness	—	%	6	%	6	%
Household	—		—		1
Lifestyle	—		5		3
International	—		19		16
Corporate and Other	—		70		74
Total	—	%	100	%	100	%

(3)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.

All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.

NOTE 13. SEGMENT RESULTS (Continued)

Net sales to the Company’s largest customer, Walmart Inc. and its affiliates, as a percentage of consolidated net sales, were 27% for both the three months ended September 30, 2023 and 2022.

The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the periods indicated:


	Net sales
	Three months ended
	9/30/2023		9/30/2022
Cleaning	32	%	33	%
Professional Products	4		5

Health and Wellness	36	%	38	%
Bags and Wraps	11		11
Cat Litter	8		8
Grilling	5		5
Household	24	%	24	%
Food	9		10
Natural Personal Care	3		4
Water Filtration	5		5
Lifestyle	17	%	19	%
International	19	%	16	%
Corporate and Other	4	%	3	%
Total	100	%	100	%

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Clorox Company
(Dollars in millions, except per share data)

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. The following discussion of the Company’s financial condition and results of operations should be read in conjunction with MD&A and the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, which was filed with the SEC on August 10, 2023, and the unaudited condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q (this Report). Unless otherwise noted, MD&A compares the three month period ended September 30, 2023 (the current period) to the three month period ended September 30, 2022 (the prior period), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate.

EXECUTIVE OVERVIEW

The Clorox Company is a leading multinational manufacturer and marketer of consumer and professional products with approximately 8,700 employees worldwide. The Company has operations in approximately 25 countries or territories and sells its products in more than 100 markets, primarily through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet and military stores; third-party and owned e-commerce channels; and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach, cleaning and disinfecting products, Pine-Sol® and Tilex® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Glad® bags and wraps; Fresh Step® cat litter; Kingsford® grilling products; Hidden Valley® dressings, dips, seasonings and sauces; Burt’s Bees® natural personal care products; Brita® water-filtration products; and Natural Vitality®, RenewLife®, NeoCell® and Rainbow Light® vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro™ and Clorox Healthcare® brand names.

The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products, which can be found in about nine of 10 U.S. homes, compete with other nationally advertised brands within each category and with “private label” brands. About 80% of the Company’s sales are generated from brands that hold the No. 1 or No. 2 market share position in their categories.

•Health and Wellness consists of cleaning, disinfecting and professional products mainly marketed and sold in the United States. Products within this segment include home care cleaning products and laundry additives primarily under the Clorox®, Clorox2®, Pine-Sol, Scentiva®, Tilex, Liquid-Plumr, and Formula 409® brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; and professional food service products under the Hidden Valley brand.

•Household consists of bags and wraps, cat litter and grilling products marketed and sold in the United States. Products within this segment include bags and wraps under the Glad brand; cat litter primarily under the Fresh Step and Scoop Away® brands; and grilling products under the Kingsford brand.

•Lifestyle consists of food, natural personal care products and water-filtration products marketed and sold in the United States. Products within this segment include dressings, dips, seasonings and sauces, primarily under the Hidden Valley brand; natural personal care products under the Burt’s Bees brand; and water-filtration products under the Brita brand.

•International consists of products sold outside the United States. Products within this segment include laundry additives; home care products; water-filtration products; digestive health products; grilling products; cat litter; food; bags and wraps; natural personal care products; and professional cleaning and disinfecting products marketed primarily under the Clorox, Ayudin®, Clorinda®, Poett, Pine-Sol, Glad, Brita, RenewLife, Ever Clean® and Burt’s Bees brands.

RECENT EVENTS AFFECTING THE COMPANY

Cyberattack

The effects of the cyberattack are expected to negatively impact fiscal year 2024 results, though some of the anticipated net sales not recognized in the first quarter as a result of the disruptions are expected to be recognized in subsequent quarters of fiscal year 2024 as customers rebuild inventories.

The Company also incurred incremental expenses of approximately $24 as a result of the cyberattack for the three months ended September 30, 2023. These costs relate to third-party consulting services, including IT recovery and forensic experts and other professional services incurred to investigate and remediate the attack, as well as incremental operating costs incurred from the resulting disruption to the Company’s business operations. The Company expects to incur additional costs related to the cyberattack in future periods.

The Company has not recognized any insurance proceeds in the three months ended September 30, 2023 related to the cyberattack. The timing of recognizing insurance recoveries, if any, may differ from the timing of recognizing the associated expenses.

Other Recent Events

For the fiscal quarter ended September 30, 2023, the Company continued to experience an inflationary environment marked by persistently unfavorable commodity costs and higher manufacturing and logistics costs. Additionally, the Company is monitoring macroeconomic conditions as a result of increased interest rates and volatility in capital markets. These evolving challenges contributed to a highly dynamic operating environment as the Company continued its efforts to drive growth, rebuild margins and drive its transformation.

The risks of future negative impacts due to transportation, logistical or supply constraints and higher commodity costs for certain raw materials remain present, and the Company continues to experience corresponding incremental costs and gross margin pressures. For fiscal year 2024, the Company anticipates the operating environment will remain volatile and challenging. Inflationary headwinds are expected to continue and consumers may feel greater pressure as continued macroeconomic uncertainty impacts spending. The Company will continue to invest in its brands, capabilities and people to deliver consistent, profitable growth over time. The Company announced and began implementing a streamlined operating model in fiscal year 2023 and will continue with its implementation in fiscal year 2024.

The impact of continued inflationary pressures, macroeconomic conditions and geopolitical instability, including ongoing conflicts in the Middle East and Ukraine, rising tensions between China and Taiwan and actual and potential shifts in U.S. and foreign trade, economic and other policies, have increased global macroeconomic and political uncertainty regarding the duration and resolution of the conflicts, the potential escalation of tensions and potential economic and global supply chain disruptions. These factors are difficult to predict considering the rapidly evolving landscape as the Company continues to expect a variable operating environment going forward.

For further discussion, refer to Item 1.A, “Risk Factors” of this report and “Risk Factors” included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023.

RESULTS OF OPERATIONS

CONSOLIDATED RESULTS


	Three months ended
	9/30/2023		9/30/2022		% Change
Net sales	$	1,386	$	1,740	(20)	%


	Three months ended September 30, 2023
	Percentage change versus the year-ago period
	Reported (GAAP) Net Sales Growth / (Decrease)		Reported Volume		Acquisitions & Divestitures		Foreign Exchange Impact		Price/Mix/ Other (1)		Organic Sales Growth / (Decrease) (Non-GAAP) (2)		Organic Volume (3)
Health and Wellness	(23)	%	(29)	%	—	%	—	%	6	%	(23)	%	(29)	%
Household	(23)		(30)		—		—		7		(23)		(30)
Lifestyle	(28)		(37)		—		—		9		(28)		(37)
International	(5)		(13)		—		(14)		22		9		(13)
Total Company (4)	(20)	%	(26)	%	—	%	(2)	%	8	%	(18)	%	(26)	%

(1)This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.

(2)Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of any acquisitions and divestitures and foreign exchange rate changes. See “Non-GAAP Financial Measures” below for reconciliation of organic sales growth / (decrease) to net sales growth / (decrease), the most directly comparable GAAP financial measure.

(3)Organic volume represents volume excluding the effect of any acquisitions and divestitures.

(4)Total Company includes Corporate and Other.

Net sales and volume in the current period decreased by 20% and 26%, respectively, primarily driven by lower volume resulting from the cyberattack. The variance between volume and net sales was primarily due to the impact of favorable price mix.


	Three months ended
	9/30/2023			9/30/2022			% Change
Gross profit	$	532		$	626		(15)	%
Gross margin	38.4		%	36.0		%

Gross margin increased by 240 basis points in the current period from 36.0% to 38.4%. The increase was primarily driven by the benefit of pricing and cost savings, partially offset by the impact of lower volume.

Expenses


	Three months ended
							% of Net Sales
	9/30/2023		9/30/2022		% Change		9/30/2023		9/30/2022
Selling and administrative expenses	$	276	$	261	6	%	19.9	%	15.0	%
Advertising costs	165		161		2		11.9		9.3
Research and development costs	29		32		(9)		2.1		1.8

Selling and administrative expenses, as a percentage of net sales, increased by 490 basis points in the current period versus the prior period. The increase in selling and administrative expenses as a percentage of net sales was primarily due to an arbitral decision relating to a commercial dispute, incremental costs associated with the cyberattack and the Company’s digital capabilities and productivity enhancements investment, partially offset by the benefit of cost savings primarily related to implementation of the streamlined operating model.

RESULTS OF OPERATIONS (Continued)

For further information regarding the cyberattack and the Company’s digital capabilities and productivity enhancements investment, see Non-GAAP Financial Measures.

Advertising costs, as a percentage of net sales, increased by 260 basis points in the current period versus the prior period as a result of lower net sales from the cyberattack, while dollars were essentially flat. The Company’s U.S. retail advertising spend as a percentage of net sales increased from 11% to 14% versus the prior period.

Research and development costs, both as a percentage of net sales and dollars, were essentially flat in the current period as compared to the prior period. The Company continues to invest behind product innovation and cost savings.

Interest expense, Other (income) expense, net and the effective tax rate on earnings


	Three months ended
	9/30/2023		9/30/2022

Interest expense	21		$	22
Other (income) expense, net	12		34
Effective tax rate on earnings	14.6	%	25.0		%

Other (income) expense, net was $12 and $34 in the current and prior period, respectively. The variance was primarily due to restructuring and related implementation costs associated with the streamlined operating model incurred in the prior period.

Restructuring and related costs

Once fully implemented, the Company expects annual cost savings to be approximately $75 to $100 annually, with benefits of $35 realized in fiscal year 2023 and benefits of approximately $45 to $50 anticipated in fiscal year 2024. The benefits of the streamlined operating model are currently expected to increase future cash flows as a result of cost savings that will be generated primarily in the areas of selling and administration, supply chain, marketing and research and development.

The Company incurred $60 of costs in fiscal year 2023 and anticipates incurring approximately $30 to $40 of costs in fiscal year 2024 related to this initiative of which approximately $10 to $15 are expected to be employee-related costs to reduce certain staffing levels such as severance payments, with the remainder for consulting and other costs. Costs incurred are expected to be settled primarily in cash.

Restructuring and related implementation costs, net were $0 for the three months ended September 30, 2023. Restructuring and related implementation costs, net were $19 for the three months ended September 30, 2022, of which $16 was related to employee-related costs and $3 was related to other costs. For further details on the streamlined operating model and restructuring, refer to the notes to condensed consolidated financial statements.

The effective tax rate on earnings was 14.6% for the current period and 25.0% for the prior period. The lower tax rate on earnings was primarily driven by the impact of temporary relief provided by the Internal Revenue Service relating to U.S. foreign tax credit regulations.

Diluted net earnings per share


	Three months ended
	9/30/2023		9/30/2022		% Change
Diluted net earnings per share	$	0.17	$	0.68	(75)	%

Diluted net earnings per share (EPS) decreased by $0.51, or 75%, in the current period, primarily due to the impact of lower volume, partially offset by the benefits of pricing and cost savings.

SEGMENT RESULTS

The following presents the results of the Company’s reportable segments and Corporate and Other (see notes to condensed consolidated financial statements for further discussion of the principle measure of segment profitability used by management, segment adjusted earnings (losses) before interest and income taxes (segment adjusted EBIT)):


	Net sales
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	504	$	657
Household	325		423
Lifestyle	229		320
International	270		285
Corporate and Other	58		55
Total	$	1,386	$	1,740


	Segment adjusted EBIT (1)
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	104	$	133
Household	(4)		22
Lifestyle	19		60
International	34		23
Corporate and Other	(62)		(63)
Total	$	91	$	175
Interest income	10		2
Interest expense	(21)		(22)

Cyberattack costs	(24)		—
Streamlined operating model	—		(19)
Digital capabilities and productivity enhancements investment	(27)		(20)
Earnings before income taxes	$	29	$	116

(1)See “Non-GAAP Financial Measures” below for reconciliation of segment adjusted EBIT to earnings (losses) before income taxes, the most directly comparable GAAP financial measure.

Health and Wellness


	Three months ended
	9/30/2023		9/30/2022		% Change
Net sales	$	504	$	657	(23)	%
Segment adjusted EBIT	104		133		(22)

Volume, net sales and segment adjusted EBIT decreased by 29%, 23% and 22% respectively, during the current period. The volume and net sales decreases were primarily due to operational disruptions resulting from the cyberattack. The variance between volume and net sales was primarily due to the benefit of price increases. The decrease in segment adjusted EBIT in the current period was primarily due to lower volume partially offset by the benefits of pricing.

Household


	Three months ended
	9/30/2023		9/30/2022		% Change
Net sales	$	325	$	423	(23)	%
Segment adjusted EBIT	(4)		22		(118)

SEGMENT RESULTS (Continued)

Volume, net sales and segment adjusted EBIT decreased by 30%, 23% and 118%, respectively, during the current period. The volume and net sales decreases were primarily due to operational disruptions resulting from the cyberattack. The variance between volume and net sales was primarily due to the benefit of price increases. The decrease in segment adjusted EBIT was mainly due to lower volume, partially offset by cost savings and the benefit of pricing.

Lifestyle


	Three months ended
	9/30/2023		9/30/2022		% Change
Net sales	$	229	$	320	(28)	%
Segment adjusted EBIT	19		60		(68)

Volume, net sales and segment adjusted EBIT decreased by 37%, 28% and 68% respectively, during the current period. The volume and net sales decreases were primarily due to operational disruptions resulting from the cyberattack. The variance between volume and net sales was mainly due to the benefit of mix and price increases. The decrease in segment adjusted EBIT was due to lower volume partially offset by lower manufacturing and logistics costs.

International


	Three months ended
	9/30/2023		9/30/2022		% Change
Net sales	$	270	$	285	(5)	%
Segment adjusted EBIT	34		23		48

Volume and net sales decreased by 13% and 5% respectively, and segment adjusted EBIT increased by 48% during the current period. The volume decrease was primarily due to operational disruptions resulting from the cyberattack. The variance between volume and net sales was mainly due to the benefit of price increases, partially offset by unfavorable foreign currency exchange rates. The increase in segment adjusted EBIT was primarily due to the net impact of pricing, partially offset by unfavorable foreign currency exchange rates and lower volume.

Argentina

Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, and as a result the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina are recognized in Other (income) expense, net in the condensed consolidated statement of earnings, utilizing the official Argentine government exchange rate.

The business environment in Argentina continues to be challenging due to significant volatility in Argentina’s currency, high inflation, economic recession and temporary price controls. As of September 30, 2023 and June 30, 2023, the net asset position, excluding goodwill, of Clorox Argentina was $44 and $48, respectively. Of these net assets, cash balances were approximately $23 and $28 as of September 30, 2023 and June 30, 2023, respectively. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for both the three months ended September 30, 2023 and the fiscal year ended June 30, 2023.

For additional information on the impacts of, and our response to, the business environment in Argentina, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023.

Corporate and Other

Corporate and Other includes certain non-allocated administrative costs, the VMS business and various other non-operating income and expenses.


	Three months ended
	9/30/2023		9/30/2022		% Change
Net Sales	$	58	$	55	5	%
Segment adjusted EBIT	(62)		(63)		(2)

SEGMENT RESULTS (Continued)

Net sales increased by 5% due to higher net sales in the VMS business. Segment adjusted EBIT was essentially flat for the period.

FINANCIAL POSITION AND LIQUIDITY

The Company’s financial condition and liquidity remained strong as of September 30, 2023. The following table summarizes cash activities:


	Three months ended
	9/30/2023		9/30/2022
Net cash provided by operations	$	20	$	178
Net cash used for investing activities	(23)		(45)
Net cash provided by (used for) financing activities	155		(35)

Operating Activities

Net cash provided by operations was $20 in the current three month period, compared with $178 in the prior three month period. The decrease was primarily driven by higher employee incentive compensation paid in the current three month period and lower cash earnings in the current three month period, partially offset by lower working capital. The lower cash earnings and decrease in working capital in the current three month period, primarily due to lower Accounts Receivable, were a result of the operational disruption due to the cyberattack.

Payment Terms Extension and Supply Chain Financing

The Company initiated the extension of its payment terms with its suppliers in the second half of fiscal year 2020 in order to improve working capital as part of and to fund the IGNITE strategy and in keeping with evolving market practices. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The Company’s operating cash flows are directly impacted as a result of the extension of the payment terms with the suppliers.

As part of those ongoing efforts, the Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. There would not be an expected material impact to the Company’s liquidity or capital resources if the financial institution or a supplier terminated the SCF arrangement. While the Company does not have direct access to information on, or influence over, which invoices a participating supplier elects to sell to the financial institution, the Company expects that the majority of these amounts have been sold to the financial institution. Refer to the notes to the condensed consolidated financial statements for detail on the SCF program.

Investing Activities

Net cash used for investing activities was $23 in the current three month period, compared with $45 in the prior three month period. The year-over-year decrease was mainly due to the timing of payments in the current three month period as a result of the operational disruption due to the cyberattack.

Financing Activities

Net cash provided by financing activities was $155 in the current three month period, compared with net cash used for financing activities of $35 in the prior three month period. The year-over-year increase was mainly due to higher cash sourced from short term borrowings in the current three month period.

Capital Resources and Liquidity

The Company's current liabilities may periodically exceed current assets as a result of the Company's debt management policies, including the Company's use of commercial paper borrowings which fluctuates depending on the amount and timing of operating and investing cash flows and payments for shareholder transactions such as dividends. The Company continues to take actions to address some of the effects of such cost increases, which include implementing price increases, driving cost savings and optimizing the Company’s supply chain.

Notwithstanding potential unforeseen adverse market conditions and as part of the Company’s regular assessment of its cash needs, the Company believes it will have the funds necessary to support its short- and long-term liquidity and operating needs, including the costs related to the announced streamlined operating model and its digital capabilities and productivity enhancements investment, as well as the costs and impacts of the business disruption associated with the cyberattack, based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings and current borrowing availability.

FINANCIAL POSITION AND LIQUIDITY (Continued)

Credit Arrangements

As of September 30, 2023, the Company maintained a $1,200 revolving credit agreement that matures in March 2027 (the Credit Agreement). There were no borrowings under the Credit Agreement as of September 30, 2023 and June 30, 2023, and the Company believes that borrowings under the Credit Agreement are and will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0, calculated as total earnings before interest, taxes, depreciation and amortization and other similar non-cash charges and certain other items (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement.

The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of September 30, 2023 and anticipates being in compliance with all restrictive covenants for the foreseeable future.

As of September 30, 2023, the Company maintained $33 of foreign and other credit lines, of which $11 was outstanding.

Stock Repurchases and Dividend Payments

As of September 30, 2023, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date. There were no share repurchases of common stock during the three months ended September 30, 2023 and 2022.

Dividends per share declared and total dividends paid to Clorox stockholders were as follows for the periods indicated:


	Three months ended
	9/30/2023		9/30/2022
Dividends per share declared	$	2.40	$	2.36
Total dividends paid	149		145

CONTINGENCIES

See notes to condensed consolidated financial statements for information on the Company’s contingencies.

RECENTLY ISSUED ACCOUNTING STANDARDS

See notes to condensed consolidated financial statements for a summary of recently issued accounting standards relevant to the Company.

NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures that are included in this MD&A and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.

Adjusted earnings (losses) before interest and income taxes (adjusted EBIT) represents earnings (losses) before income taxes excluding interest income, interest expense and other significant items that are nonrecurring or unusual (such as incremental costs related to the cyberattack, asset impairments, charges related to the streamlined operating model, charges related to the digital capabilities and productivity enhancements investment, significant losses/(gains) related to acquisitions and other nonrecurring or unusual items impacting comparability). The Company uses this measure to assess the operating results and performance of its segments, perform analytical comparisons, identify strategies to improve performance, and allocate resources to each segment. Management believes that the presentation of adjusted EBIT is useful to investors to assess operating performance on a consistent basis by removing the impact of the items that management believes does not directly reflect the performance of each segment's underlying operations. Adjusted EBIT margin is the ratio of adjusted EBIT to net sales.


	Reconciliation of earnings (losses) before income taxes to adjusted EBIT
	Three months ended
	9/30/2023		9/30/2022
Earnings (losses) before income taxes	$	29	$	116
Interest income	(10)		(2)
Interest expense	21		22

Cyberattack costs (1)	24		—
Streamlined operating model (2)	—		19
Digital capabilities and productivity enhancements investment (3)	27		20
Adjusted EBIT	$	91	$	175

(1)Represents incremental costs incurred as a result of the cyberattack the Company experienced in the first quarter of fiscal year 2024. Due to the nature, scope and magnitude of these costs, the Company’s management believes presenting theses costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the Company’s operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by Company management. See notes to condensed consolidated financial statements for additional information.

(2)Represents restructuring and related implementation costs, net for the streamlined operating model. Due to the nonrecurring and unusual nature of these costs, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period over period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management. See notes to condensed consolidated financial statements for additional information.

(3)Represents expenses related to the Company's digital capabilities and productivity enhancements investment. Due to the nature, scope and magnitude of this investment, these costs are considered by management to represent incremental transformational costs above the historical normal level of spending for information technology to support operations. Since these strategic investments, including incremental operating costs, will cease at the end of the investment period, are not expected to recur in the foreseeable future and are not considered representative of the company's underlying operating performance, the company's management believes presenting these costs as an adjustment in the non-GAAP results provides additional information to investors about trends in the company's operations and is useful for period-over-period comparisons. It also allows investors to view underlying operating results in the same manner as they are viewed by company management.

Of the total $500 million investment, approximately 65% is expected to represent incremental operating costs primarily recorded within selling and administrative expenses to be adjusted from reported Earnings (losses) before income taxes for purposes of disclosing adjusted EBIT over the course of the next five years. About 70% of these operating costs are expected to be related to the implementation of the ERP, with the remaining costs primarily related to the implementation of complementary technologies.

During the three months ended September 30, 2023 and 2022, the Company incurred approximately $27 and $20, respectively, of operating expenses related to its digital capabilities and productivity enhancements investment. The expenses relate to the following:


	Three months ended
	9/30/2023		9/30/2022
External consulting fees (1)	$	21	$	16
IT project personnel costs (2)	2		1
Other (3)	4		3
Total	$	27	$	20

NON-GAAP FINANCIAL MEASURES (Continued)

(1)Comprised of third-party consulting fees incurred to assist in the project management and the preliminary project stage of this transformative investment. The Company relies on consultants for certain capabilities required for these programs that the Company does not maintain internally. These costs support the implementation of these programs incremental to the Company's normal IT costs and will not be incurred following implementation.

(2)Comprised of labor costs associated with internal IT project management teams that are utilized to oversee the new system implementations. Given the magnitude and transformative nature of the implementations planned, the necessary project management costs are incremental to the historical levels of spend and will no longer be incurred subsequent to implementation. As a result of this long-term strategic investment, the Company considers these costs not reflective of the ongoing costs to operate its business.

(3)Comprised of various other expenses associated with the Company’s new system implementations, including company personnel dedicated to the project that have been backfilled with either permanent or temporary resources in positions that are considered part of normal operating expenses.

Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions and divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the Company was operating and expects to continue to operate throughout the relevant periods, and the Company’s estimate of the impact of foreign exchange rate changes, which are difficult to predict and out of the control of the Company and management.

The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:


	Three months ended September 30, 2023
	Percentage change versus the year-ago period
	Health and Wellness		Household		Lifestyle		International		Total Company (1)
Net sales growth / (decrease) (GAAP)	(23)	%	(23)	%	(28)	%	(5)	%	(20)	%
Add: Foreign Exchange	—		—		—		14		2
Add/(Subtract): Divestitures / Acquisitions	—		—		—		—		—
Organic sales growth / (decrease) (non-GAAP)	(23)	%	(23)	%	(28)	%	9	%	(18)	%

(1)Total Company includes Corporate and Other.

Cautionary Statement

This Report, including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements regarding the expected or potential impact of the Company’s operational disruption stemming from a cyberattack, and any such forward-looking statements involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, and in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to:

•unfavorable general economic and geopolitical conditions beyond our control, including supply chain disruptions, labor shortages, wage pressures, rising inflation, the interest rate environment, fuel and energy costs, foreign currency exchange rate fluctuations, weather events or natural disasters, disease outbreaks or pandemics, such as COVID-19, terrorism, and unstable geopolitical conditions, including ongoing conflicts in the Middle East and Ukraine and rising tensions between China and Taiwan, as well as macroeconomic and geopolitical volatility and uncertainty as a result of a number of these and other factors, including actual and potential shifts between the U.S. and its trading partners, especially China;

CAUTIONARY STATEMENT (Continued)

•volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services;

•the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;

•the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;

•risks related to supply chain issues, product shortages and disruptions to the business, as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers;

•intense competition in the Company’s markets;

•risks related to the Company’s use of and reliance on information technology systems, including potential and actual security breaches, cyberattacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, business, service or operational disruptions, or that impact the Company’s financial results or financial reporting, or any resulting unfavorable outcomes, increased costs or legal proceedings;

•the ability of the Company to implement and generate cost savings and efficiencies, and successfully implement its transformational initiatives or strategies, including achieving anticipated benefits and cost savings from the implementation of the streamlined operating model and digital capabilities and productivity enhancements;

•dependence on key customers and risks related to customer consolidation and ordering patterns;

•the Company’s ability to attract and retain key personnel, which may continue to be impacted by challenges in the labor market, such as wage inflation and sustained labor shortages;

•the Company’s ability to maintain its business reputation and the reputation of its brands and products;

•lower revenue, increased costs or reputational harm resulting from government actions and compliance with regulations, or any material costs imposed by changes in regulation;

•changes to our processes and procedures as a result of our digital capabilities and productivity enhancements investment that may result in changes to the Company’s internal controls over financial reporting;

•the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;

•risks related to international operations and international trade, including changing macroeconomic conditions as a result of inflation, volatile commodity prices and increases in raw and packaging materials prices, labor, energy and logistics; global economic or political instability; foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls; changes in governmental policies, including trade, travel or immigration restrictions, new or additional tariffs, and price or other controls; labor claims and civil unrest; continued high levels of inflation in Argentina; potential operational or supply chain disruptions from wars and military conflicts, including the conflict in Ukraine; impact of the United Kingdom’s exit from the European Union; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;

•the impact of Environmental, Social, and Governance (ESG) issues, including those related to climate change and sustainability on our sales, operating costs or reputation;

•the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;

•the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls;

•the COVID-19 pandemic and related impacts, including on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any significant disruption to such systems; on the demand for and sales of the Company’s products; and on worldwide, regional and local adverse economic conditions;

CAUTIONARY STATEMENT (Continued)

•risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill, in particular the impairment charges related to the carrying value of the Company’s VMS business; and the ability to complete announced transactions and, if completed, integration costs and potential contingent liabilities related to those transactions;

•the accuracy of the Company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based;

•risks related to increases in the estimated fair value of P&G’s interest in the Glad business;

•environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;

•the Company’s ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by the Company of third-party intellectual property rights;

•the performance of strategic alliances and other business relationships;

•the effect of the Company’s indebtedness and credit rating on its business operations and financial results and the Company’s ability to access capital markets and other funding sources, as well as the cost of capital to the Company;

•the Company’s ability to pay and declare dividends or repurchase its stock in the future;

•the impacts of potential stockholder activism; and

•risks related to any litigation associated with the exclusive forum provision in the Company’s bylaws.

The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have not been any material changes to the Company’s market risk since June 30, 2023. For additional information, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023.

Item 4. Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

On Monday, August 14, 2023, the Company disclosed it had identified unauthorized activity on some of its Information Technology (IT) systems; see Note 2 in the condensed consolidated financial statements in this Report. That activity began on Friday, August 11, 2023 and after becoming aware of it that evening, the Company immediately began taking steps to stop and remediate the activity. The Company also took certain systems offline and engaged third-party cybersecurity experts to support its investigation and recovery efforts. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers. However, the incident resulted in wide-scale disruptions to the Company’s business operations throughout the remainder of the quarter.

During the disruptions caused by the cyberattack, we deployed additional interim controls in response to taking certain systems offline during the period to maintain our internal control over financial reporting.

Other than the additional interim controls and procedures implemented in connection with the execution of the Company’s existing business continuity plans as a result of the cyberattack discussed above, no change in the Company’s internal control over financial reporting occurred during the first fiscal quarter of the fiscal year ending June 30, 2024, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.A. Risk Factors

For information regarding Risk Factors, please refer to Item 1.A. in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, as supplemented by the following revised risk factor, and the information in “Cautionary Statement” included in this Report.

Failure of key technology systems, cyberattacks, privacy breaches or data breaches could have a material adverse effect on the Company’s business, financial condition, results of operations and reputation.

To conduct its business, the Company relies extensively on information and operational technology systems, many of which are managed, hosted, provided and/or used by third parties and their vendors. These systems include, but are not limited to, programs and processes relating to communicating within the Company and with customers, consumers, vendors, investors and other parties; ordering and managing materials from suppliers; converting materials to finished products; receiving and processing purchase orders and shipping products to customers; processing transactions; storing, processing and transmitting data, including personal confidential information and payment card industry data; hosting, processing and sharing confidential and proprietary research, business and financial information; and complying with financial reporting, regulatory, legal and tax requirements. Furthermore, the Company sells certain of its natural personal care products, vitamins, minerals, supplements and other products directly to consumers online and through websites, mobile apps and connected devices, and the Company also engages in online activities, including promotions, rebates and customer loyalty and other programs, through which it may receive personal information. Through the use of any of these information and operational technology systems or processes, the Company or its vendors have in the past and could in the future again experience cyberattacks, privacy breaches, data breaches or other incidents that may result in unauthorized access, disclosure and misuse of consumer, customer, employee, vendor or Company information, especially as the Company continues operating under a hybrid working model under which employees can work and access the Company’s technology infrastructure remotely. A breach or other breakdown in the Company’s technology, including a cyberattack, privacy breach, data breach or other incident involving the Company or any of the Company's third-party service providers or vendors could adversely affect the Company’s financial condition and results of operations.

On August 14, 2023, the Company disclosed that it had identified unauthorized activity on some of its IT systems and took immediate steps to stop and remediate the activity, including taking certain systems offline. The Company implemented its business continuity plans, including manual ordering and processing procedures at a reduced rate of operations in order to continue servicing its customers, which resulted in an elevated level of consumer product availability issues.

Based on the information currently available, the Company believes the cyberattack is contained due to the steps the Company has taken to address the incident. However, due to the order processing delays and elevated level of product outages, the incident has negatively impacted the Company's fiscal first quarter financial results, and is expected to negatively impact its fiscal 2024 financial results. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Based on its current assessment of the situation, the Company expects to experience ongoing, but lessening, operational impacts in the fiscal second quarter as it makes progress in returning to normalized operations. The cyberattack may also lead to additional regulatory scrutiny or litigation exposure.

The cyberattack also damaged portions of the Company’s IT infrastructure, which caused wide-scale disruption of the Company’s operations. The Company is repairing its infrastructure and is reintegrating the systems that it took offline. For more information regarding this incident, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Note 2. Cyberattack”.

In addition to repairing its infrastructure as a result of the cyberattack, the Company is in the process of a multi-year phased upgrade of its digital capabilities, including enhancing operating efficiencies and transitioning to a cloud-based platform, as well as replacing its enterprise resource planning system. It also uses various other hardware, software and operating systems that may need to be upgraded or replaced in the near future as such systems cease to be supported by third-party service providers, and may be vulnerable to increased risks, including the risk of further security breaches, system failures and disruptions. Any such upgrade could take time, oversight and be costly to the Company, and may include potential challenges, such as the cost of training personnel, migration of data, the potential instability of the new system and cost overruns. If such systems are not successfully upgraded or replaced in a timely manner, system outages, disruptions or delays, or other issues may arise. If a new system does not function properly or is not adequately supported by third-party service providers and processes, it could adversely affect the Company’s business and operations, which, in turn, could adversely impact the Company’s results of operations and cash flows.

Despite the security measures the Company has in place, the information and operational technology systems, including those of our customers, vendors, suppliers and other third-party service providers with whom we have contracted, have, in the past,

ITEM 1.A. RISK FACTORS (Continued)

and may, in the future, be vulnerable to cyber-threats such as computer viruses or other malicious codes, security breaches, unauthorized access, phishing attacks and other disruptions from employee error, unauthorized uses, system failures, including Internet outages, unintentional or malicious actions of employees or contractors or cyberattacks by hackers, criminal groups, nation-states and nation-state-sponsored organizations and social-activist organizations. The Company’s information and operational technology systems and its third-party providers’ systems, have been, and will continue to be, subject to cyber-threats such as computer viruses or other malicious codes, ransomware, unauthorized access attempts, business email compromise, cyber extortion, denial of service attacks, phishing, social engineering, hacking and other cyberattacks attempting to exploit vulnerabilities. The Company has seen and may continue to see an increase in the number of such attacks, especially as the Company continues operating under a hybrid working model under which employees can work and access the Company’s technology infrastructure remotely. In addition, while we have purchased cybersecurity insurance, costs related to a cyberattack may exceed the amount of insurance coverage or be excluded under the terms of our cybersecurity insurance policy. As cyberattacks increase in frequency and magnitude, we may be unable to obtain cybersecurity insurance in amounts and on terms we view as appropriate for our operations.

The Company’s security efforts and the efforts of its third-party providers may not prevent or timely detect future attacks and resulting breaches or breakdowns of the Company’s, or its third-party service providers’, databases or systems. In addition, if the Company or its third-party providers are unable to effectively resolve such breaches or breakdowns on a timely basis, the Company may experience interruptions in its ability to manage or conduct business, as well as reputational harm, governmental fines, penalties, regulatory proceedings, and litigation and remediation expenses. In addition, such incidents could result in unauthorized disclosure and misuse of material confidential information, including personal identifying information.

Cyber-threats are becoming more sophisticated, are constantly evolving and are being made by groups and individuals with a wide range of expertise and motives, and this increases the difficulty of detecting and successfully defending against them. We have incurred, and will continue to incur, expenses to comply with privacy and data protection standards and protocols imposed by law, regulation, industry standards and contractual obligations. Increased regulation of data collection, use, and retention practices, including self-regulation and industry standards, changes in existing laws and regulations, including reporting requirements, enactment of new laws and regulations, increased enforcement activity, and changes in interpretation of laws, could increase our cost of compliance and operation, limit our ability to grow our business or otherwise harm our business.

In addition, data breaches or theft of personal information collected by the Company and its third-party service providers as well as data breaches or theft of Company information and assets have occurred in the past and may occur in the future. The Company is subject to the laws and regulations of various countries where it operates or does business related to solicitation, collection, processing, transferring, storing or use of consumer, customer, vendor or employee information or related data. These laws and regulations change frequently, and new legislation continues to be introduced and may be interpreted and applied differently from jurisdiction to jurisdiction and may create inconsistent or conflicting requirements. The changes introduced by data privacy and protection regulations increase the complexity of regulations enacted to protect business and personal data and they subject the Company to additional costs and have required, and may in the future require, costly changes to the Company’s security systems, policies, procedures and practices. These laws and regulations also may result in the Company incurring additional expenses and liabilities in the event of unauthorized access to or disclosure of personal data.

These risks also may be present to the extent any of our partners, distributors, joint venture partners or suppliers using separate information or operational technology systems, not integrated with the systems of the Company, suffers a cyberattack and could result in increased costs related to our involvement in investigations or notifications conducted by these third parties. These risks may also be present to the extent a business we have acquired, that does not use our information or operational technology systems, experiences a system shutdown, service disruption, or cyberattack.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (the 2018 Open-Market Program), which has no expiration date.

In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.

The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the first quarter of fiscal year 2024.

[a]

[b]

[c]

[d]

Period

Total Number of
Shares Purchased

Average Price Paid

per Share (1)

Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs

Maximum Number (or
Approximate Dollar
Value) of Shares that
May Yet Be Purchased
Under the Plans or
Programs

July 1 to 31, 2023

—

$993 million

August 1 to 31, 2023

—

$993 million

September 1 to 30, 2023

—

$993 million

Total

—

(1)Average price paid per share in the period includes commission.

Item 5. Other Information

During the three months ended September 30, 2023, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange act or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(c) of Regulation S-K.

Item 6. Exhibits

See Exhibit Index below, which is incorporated by reference herein.

EXHIBIT INDEX


Exhibit Number						Exhibit Description
10.1						T he Clorox Company Annual Incentive Plan, amended and restated as of September 20, 2023
31.1						Certification by the Chief Executive Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2						Certification by the Chief Financial Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32						Certification by the Chief Executive Officer and Chief Financial Officer of the Company Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH						XBRL Taxonomy Extension Schema Document.
101.CAL						XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF						XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB						XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		THE CLOROX COMPANY
		(Registrant)


DATE: November 1, 2023	BY	/s/ Laura Peck
		Laura Peck Vice President – Chief Accounting Officer and Corporate Controller

Exhibit 10.1

THE CLOROX COMPANY

ANNUAL INCENTIVE PLAN

As Amended and Restated Effective

as of September 20, 2023 (the “Effective Date”)

1.Purpose.

The purpose of The Clorox Company Annual Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of substantial responsibility and to provide an incentive for employees of The Clorox Company, a Delaware corporation (the “Company”) and its subsidiaries and to recognize and reward those employees. The Company’s executives are eligible to earn short-term cash incentive awards under this Plan.

2.Definitions. The following terms will have the following meaning for purposes of the Plan:

(a)“Award” means a bonus paid in cash under the Plan.

(b)“Board” means the Board of Directors of the Company.

(c)“Chief Executive Officer” means the chief executive officer of the Company.

(d)“Chief People Officer” means the officer of the Company responsible for the Company’s human resources matters, which position is presently held by the Executive Vice President - Chief People and Corporate Affairs Officer of the Company.

(e)“Code” means the Internal Revenue Code of 1986, as amended.

(f)“Committee” means the Management Development and Compensation Committee of the Board, or such other Committee designated by the Board to administer the Plan.

(g)“Employee” means any person employed by the Company or any Subsidiary.

(h)“Executive Committee” means the executives who are members of the Company’s management executive committee.

(i)“Mid-Year Participant” means (i) an individual who becomes an Employee on or following the date that full-year Awards are granted for a Year and who is selected by the Committee to participate in the Plan during such Year or (ii) an Employee previously selected by the Committee to participate in the Plan for the Year who is subsequently promoted during such Year. For avoidance of doubt, this shall include an Employee who is promoted to a position which is eligible for participation in the Plan.

(j)“Participant” means an Employee selected by the Committee to participate in the Plan (including, for the avoidance of doubt, a Mid-Year Participant).

(k)“Retirement” means termination of employment with the Company, other than by reason of death or disability, of a Participant after (1) attaining age 65, (2) attaining age 55 with at least ten years of vesting service, which solely for purposes of this Plan, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Participant with respect to the 401(k) Plan (“Vesting Service”) or (3) 20 or more years of Vesting Service.

(l)“Section 409A” means Section 409A of the Code and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service.

(m)“Subsidiary” means any corporation in which the Company, directly or indirectly, controls 50 percent or more of the total combined voting power of all classes of stock.

(n)“Vice President” means a regular salaried Employee scheduled to work more than 20 hours per week who is in salary grade 30 or above and who is not a member of the Executive Committee, but is a Vice President.

(o)“Year” means a fiscal year of the Company.

3.Awards.

(a)Within 180 days after the beginning of each Year, the Committee will select Participants for the Year and establish in writing the method by which the Awards will be calculated for that Year; provided, that, with respect to Participants who are Mid-Year Participants, the Committee shall determine the method by which the Awards to such individuals will be calculated for the Year during which they are hired or promoted, as applicable, as soon as administratively practicable following their commencement of employment or promotion, as applicable, including whether or not the Award for such Year will be prorated. The Committee may provide for payment of all or part of the Award in the case of Retirement, death, disability or change of ownership of control of the Company or a Subsidiary during the Year in accordance with Section 409A. In addition, the Committee may provide for payment of all or part of the Award, including a prorated payment of the Award, in the event of (1) all other terminations of employment during the Year, (2) placement on medical or other leave of absence from the Company or (3) hiring or promotions during the Year in accordance with Section 409A.

(b)For the Chief Executive Officer and the Executive Committee, the Committee shall determine and certify the amount of the Award, if any, to be made. The Committee may decrease or eliminate any Award calculated under the methodology established in accordance with paragraph (a) in order to reflect additional considerations relating to performance.

(c)For Vice Presidents and all other participants, the Chief Executive Officer shall determine and certify the amount of the Award, if any, to be made. The Chief Executive Officer may increase, decrease or eliminate, any Award calculated under the methodology established in accordance with paragraph (a) in order to reflect additional considerations relating to performance.

(d)Awards will be paid to the Participants following certification and no later than ninety (90) days following the close of the Year with respect to which the Awards are made, unless all or a portion of a Participant’s Award is deferred pursuant to the Participant’s timely and validly made election made in accordance with such terms as the Company, the Board , Committee (or other committee of the Board) may determine. A timely election is one that satisfies the requirements of Section 409A and typically for performance-based compensation must be made at least six months before the end of the performance period, provided that the Participant performs services continuously from the later of the beginning of the performance period or the date the performance criteria are established through the date an election is made and provided further that in no event may a deferral be made after such compensation has become readily ascertainable as set forth in Section 409A.

(e)The Company shall withhold from the payment of any Award hereunder any amount required to be withheld for taxes.

(f)In the event of a restatement of the Company’s financial results to correct a material error resulting from fraud or intentional misconduct, as determined by the Board or the Committee, the Board, or the Committee, will review all compensation that was made pursuant to this Plan on the basis of having met or exceeded specific performance targets for performance periods beginning after June 30, 2008 which occur during the years for which financial statements are restated. If a lower payment of performance-based compensation would have been made to the Participants based upon the restated financial results, the Board or the Committee, as applicable, will, to the extent permitted by governing law and subject to the following sentence, seek to recoup for the benefit of the Company the amount by which the individual Participant’s Award(s) for the restated years exceeded the lower payment that would have been made based on the restated financial results, plus a reasonable rate of interest; provided, however, that neither the Board nor the Committee will seek to recoup Awards paid more than three years prior to the date on which the Company announces the need for the applicable financial statements to be restated. The Board, or the Committee, will only seek to recoup Awards paid to Participants whose fraud or intentional misconduct was a significant contributing factor to the need for such restatement, as determined by the Board or the Committee, as applicable. Notwithstanding the foregoing, this Section 3(f) shall not apply to Participants who are “Covered Employees” (as defined in the Company’s Policy Regarding Clawback of Incentive Compensation, the “Policy”), and Awards made to such Covered Employee shall be subject instead to the clawback provisions contained in the Policy, as provided in Section 7 hereof.

4.Termination of Employment.

Except as may be specifically provided in an Award pursuant to Section 3(a), a Participant shall have no right to an Award under the Plan for any Year in which the Participant is not actively employed by the Company or its Subsidiaries on June 30 of such Year. When establishing Awards each Year, the Committee may also provide that in the event a Participant is not employed by the Company or its Subsidiaries on the date on which the Award is paid, the Participant may forfeit such Participant’s right to the Award paid under the Plan.

5.Administration.

The Plan will be administered by the Committee. The Committee will have the authority to interpret the Plan, to prescribe rules relating to the Plan and to make all determinations necessary or advisable in administering the Plan. Decisions of the Committee with respect to the Plan will be final and conclusive. The Committee may delegate some or all of its authority as identified herein to the Chief Executive Officer or the Chief People Officer, including the power and authority to make Awards with respect to Participants who are not members of the Clorox Executive Committee or an “officer” of the Company for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to such conditions and limitations as the Committee may establish. References to the Committee in this Plan shall refer to the Chief Executive Officer or the Chief People Officer with respect to any action of such officer within the scope of the authority delegated to such officer by the Committee. The Chief Executive Officer may delegate some or all of its authority under Section 3(c) to the Chief People Officer.

6.Unfunded Plan.

Awards under the Plan will be paid from the general assets of the Company, and the rights of Participants under the Plan will be only those of general unsecured creditors of the Company.

7.Clawback.

Awards under the Plan granted to Participants who are “Covered Employees” (as defined in the Policy) are subject to clawback in accordance with the terms of the Policy, as amended from time to time, and pursuant to any other policy the Company may adopt as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of any Award granted hereunder pursuant to such a clawback policy shall be treated as an event giving rise to a Participant’s right to terminate employment for “good reason” or “constructive termination” (or any similar term) under any agreement with the Company.

8.Amendment or Termination of the Plan. The Committee may from time to time suspend, revise, amend or terminate the Plan.

9.Applicable Law.

To the extent not preempted by federal law, the Plan shall be construed in accordance with and governed by the laws of the State of California, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Plan to the substantive law of another jurisdiction.

10.No Rights to Employment.

Nothing contained in the Plan shall give any person the right to be retained in the employment of the Company or any of its Subsidiaries. The Company reserves the right to terminate any Participant at any time for any reason notwithstanding the existence of the Plan.

11.No Assignment.

Except as otherwise required by applicable law, any interest, benefit, payment, claim or right of any Participant under the Plan shall not be sold, transferred, assigned, pledged, encumbered or hypothecated by any Participant and shall not be subject in any manner to any claims of any creditor of any Participant or beneficiary, and any attempt to take any such action shall be null and void. During the lifetime of any Participant, payment of an Award shall only be made to such Participant. Notwithstanding the foregoing, the Committee may establish such procedures as it deems necessary for a Participant to designate a beneficiary to whom any amounts would be payable in the event of any Participant’s death.

12.Number and References.

Except where otherwise indicated by the context, the plural shall include the singular and the singular shall include the plural. Any reference in the Plan to a Section of the Plan either in the Plan or to an act or code or to any section thereof or rule or regulation thereunder shall be deemed to refer to such Section of the Plan, act, code, section, rule or regulation, as may be amended from time to time, or to any successor Section of the Plan, act, code, section, rule or regulation.

13.Severability.

If any one or more of the provisions contained in this Plan, or any application thereof, shall be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and all other applications thereof shall not in any way be affected or impaired thereby. This Plan shall be construed and enforced as if such invalid, illegal or unenforceable provision has never comprised a part hereof, and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the invalid, illegal or unenforceable provision or by its severance from the Plan. In lieu of such invalid, illegal or unenforceable provisions there shall be added automatically as a part hereof a provision as similar in terms and economic effect to such invalid, illegal or unenforceable provision as may be possible and be valid, legal and enforceable.

14.Requirements of Law.

The issuance of cash under the Plan shall be subject to all applicable laws and to such approvals by any governmental agencies or national securities exchanges as may be required.

15.Non-Exclusive Plan.

The adoption of the Plan by the Board shall not be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other incentive arrangements as it may deem desirable.

16.Section 409A Compliance.

To the extent applicable, it is intended that this Plan and any Awards granted hereunder comply with the requirements of Section 409A. Any provision that would cause the Plan or any Award granted hereunder to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

END OF DOCUMENT

Exhibit 31.1

CERTIFICATION

I, Linda Rendle, certify that:

1.I have reviewed this quarterly report on Form 10-Q of The Clorox Company;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 1, 2023


/s/ Linda Rendle
Linda Rendle
Chief Executive Officer

Exhibit 31.2

CERTIFICATION

I, Kevin B. Jacobsen, certify that:

1.I have reviewed this quarterly report on Form 10-Q of The Clorox Company;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 1, 2023


/s/ Kevin B. Jacobsen
Kevin B. Jacobsen
Executive Vice President - Chief Financial Officer

Exhibit 32

CERTIFICATION

In connection with the periodic report of The Clorox Company (the “Company”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), we, Linda Rendle, Chief Executive Officer of the Company, and Kevin B. Jacobsen, Executive Vice President - Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to our knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: November 1, 2023



/s/ Linda Rendle
Linda Rendle
Chief Executive Officer


/s/ Kevin B. Jacobsen
Kevin B. Jacobsen
Executive Vice President - Chief Financial Officer

Cover Page - shares	3 Months Ended
Cover Page - shares	Sep. 30, 2023	Oct. 18, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	1-07151
Entity Registrant Name	THE CLOROX COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-0595760
Entity Address, Address Line One	1221 Broadway
Entity Address, City or Town	Oakland
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94612-1888
City Area Code	510
Local Phone Number	271-7000
Title of 12(b) Security	Common Stock - $1.00 par value
Trading Symbol	CLX
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		124,059,098
Entity Central Index Key	0000021076
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net sales	$ 1,386	$ 1,740
Cost of products sold	854	1,114
Gross profit	532	626
Selling and administrative expenses	276	261
Advertising costs	165	161
Research and development costs	29	32
Interest expense	21	22
Other (income) expense, net	12	34
Earnings before income taxes	29	116
Income tax expense	4	29
Net earnings	25	87
Less: Net earnings attributable to noncontrolling interests	3	2
Net earnings attributable to Clorox	$ 22	$ 85
Net earnings per share attributable to Clorox
Basic net earnings per share (in dollars per share)	$ 0.17	$ 0.69
Diluted net earnings per share (in dollars per share)	$ 0.17	$ 0.68
Weighted average shares outstanding (in thousands)
Basic (in shares)	123,973	123,339
Diluted (in shares)	124,650	123,914
Comprehensive income	$ 24	$ 51
Less: Total comprehensive income attributable to noncontrolling interests	3	2
Total comprehensive income attributable to Clorox	$ 21	$ 49

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 518	$ 367
Receivables, net	581	688
Inventories, net	710	696
Prepaid expenses and other current assets	102	77
Total current assets	1,911	1,828
Property, plant and equipment, net of accumulated depreciation and amortization of $2,768 and $2,705, respectively	1,317	1,345
Operating lease right-of-use assets	328	346
Goodwill	1,246	1,252
Trademarks, net	541	543
Other intangible assets, net	162	169
Other assets	486	462
Total assets	5,991	5,945
Current liabilities
Notes and loans payable	347	50
Current operating lease liabilities	88	87
Accounts payable and accrued liabilities	1,678	1,659
Income taxes payable	115	121
Total current liabilities	2,228	1,917
Long-term debt	2,478	2,477
Long-term operating lease liabilities	290	310
Other liabilities	837	825
Deferred income taxes	27	28
Total liabilities	5,860	5,557
Commitments and contingencies
Stockholders’ equity
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding	0	0
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of September 30, 2023 and June 30, 2023; and 124,001,348 and 123,820,022 shares outstanding as of September 30, 2023 and June 30, 2023, respectively	131	131
Additional paid-in capital	1,246	1,245
Retained earnings	299	583
Treasury stock, at cost: 6,740,113 and 6,921,439 shares as of September 30, 2023 and June 30, 2023, respectively	(1,219)	(1,246)
Accumulated other comprehensive net (loss) income	(494)	(493)
Total Clorox stockholders’ (deficit) equity	(37)	220
Noncontrolling interests	168	168
Total stockholders’ equity	131	388
Total liabilities and stockholders’ equity	$ 5,991	$ 5,945

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Statement of Financial Position [Abstract]
Property, plant and equipment, accumulated depreciation and amortization	$ 2,768	$ 2,705
Preferred stock, par value (in dollars per share)	$ 1.00	$ 1.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 1.00	$ 1.00
Common stock, shares authorized (in shares)	750,000,000	750,000,000
Common stock, shares issued (in shares)	130,741,461	130,741,461
Common stock, shares outstanding (in shares)	124,001,348	123,820,022
Treasury stock (in shares)	6,740,113	6,921,439

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities:
Net earnings	$ 25	$ 87
Adjustments to reconcile net earnings to net cash provided by operations:
Depreciation and amortization	61	56
Stock-based compensation	13	10
Deferred income taxes	(5)	(5)
Other	1	16
Changes in:
Receivables, net	108	63
Inventories, net	(14)	(6)
Prepaid expenses and other current assets	(22)	(30)
Accounts payable and accrued liabilities	(138)	(28)
Operating lease right-of-use assets and liabilities, net	(1)	1
Income taxes payable / prepaid	(8)	14
Net cash provided by operations	20	178
Investing activities:
Capital expenditures	(24)	(46)
Other	1	1
Net cash used for investing activities	(23)	(45)
Financing activities:
Notes and loans payable, net	298	111
Cash dividends paid to Clorox stockholders	(149)	(145)
Issuance of common stock for employee stock plans and other	6	(1)
Net cash provided by (used for) financing activities	155	(35)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	0	(4)
Net increase (decrease) in cash, cash equivalents and restricted cash	152	94
Cash, cash equivalents and restricted cash:
Beginning of period	368	186
End of period	$ 520	$ 280

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2023 and 2022, in the opinion of management, reflect all normal and recurring adjustments considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company or Clorox) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2023, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies. Recently Adopted Accounting Standards In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the condensed consolidated financial statements, results of operations, or cash flows.

CYBERATTACK

3 Months Ended

Sep. 30, 2023

Unusual or Infrequent Items, or Both [Abstract]

CYBERATTACK


	Three months ended
	9/30/2023
Costs of products sold	$	11
Selling and administrative expenses	13
Total	$	24

SUPPLY CHAIN FINANCING PROGRAM	3 Months Ended
SUPPLY CHAIN FINANCING PROGRAM	Sep. 30, 2023
Payables and Accruals [Abstract]
SUPPLY CHAIN FINANCING PROGRAM	SUPPLY CHAIN FINANCING PROGRAM The Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier by selling the Company’s payables to the financial institution. Participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets, cash flows or liquidity. The Company and our subsidiaries have not pledged any assets as security or provided guarantees under the SCF program. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable and accrued liabilities in the condensed consolidated balance sheets and the associated payments are included in operating activities within the condensed consolidated statements of cash flows. As of September 30, 2023 and June 30, 2023, the amount due to suppliers participating in the SCF program and included in Accounts payable and accrued liabilities was $119 and $220, respectively. The decrease in the amount due to suppliers participating in the SCF program from June 30, 2023 to September 30, 2023 was attributable to a reduction of orders due to the temporary operational disruptions of the cyberattack along with the timing of payments.

RESTRUCTURING AND RELATED COSTS

3 Months Ended

Sep. 30, 2023

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND RELATED COSTS


	Three months ended				Inception to date ended
	9/30/2023		9/30/2022			9/30/2023
Costs of products sold	$	—	$	(1)		$	(3)
Selling and administrative expenses	—		1			12
Research and development	—		—			(1)
Other (income) expense, net:
Employee-related costs	—		19			52


Total, net	$	—	$	19		$	60

The Company may, from time to time, decide to pursue additional restructuring-related initiatives that involve costs in future periods.


	Employee-Related Costs		Other		Total
Accrual Balance as of June 30, 2023	$	23	$	5	$	28
Charges	—		—		—
Cash payments	(16)		(5)		(21)

Accrual Balance as of September 30, 2023	$	7	$	—	$	7

INVENTORIES, NET

3 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

INVENTORIES, NET

Inventories, net consisted of the following as of:


	9/30/2023		6/30/2023
Finished goods	$	618	$	595
Raw materials and packaging	178		182
Work in process	20		8
LIFO allowances	(104)		(87)
Total inventories, net	$	712	$	698
Less: Non-current inventories, net (1)	2		2
Total current inventories, net	$	710	$	696

(1)Non-current inventories, net are recorded in Other assets.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

3 Months Ended

Sep. 30, 2023

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial Risk Management and Derivative Instruments

Commodity Price Risk Management

Foreign Currency Risk Management

Interest Rate Risk Management

The Company held no interest rate contracts as of both September 30, 2023 and June 30, 2023.

Commodity, Foreign Exchange and Interest Rate Derivatives

The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:


	Gains (losses) recognized in Other comprehensive (loss) income
	Three months ended
	9/30/2023		9/30/2022
Commodity purchase derivative contracts	$	(1)	$	(3)
Foreign exchange derivative contracts	1		1
Interest rate derivative contracts	—		—
Total	$	—	$	(2)


	Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings	Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
		Three months ended
		9/30/2023		9/30/2022
Commodity purchase derivative contracts	Cost of products sold	$	(2)	$	4
Foreign exchange derivative contracts	Cost of products sold	—		1
Interest rate derivative contracts	Interest expense	3		3
Total		$	1	$	8

Counterparty Risk Management and Derivative Contract Requirements

related to exchange traded futures and options contracts of $2 and $0, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.

Trust Assets

Fair Value of Financial Instruments

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.


			9/30/2023				6/30/2023
	Balance sheet classification	Fair value hierarchy level	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets
Commodity purchase options contracts	Prepaid expenses and other current assets	1	$	—	$	—	$	2	$	2
Commodity purchase swaps contracts	Prepaid expenses and other current assets	2	1		1		—		—

Foreign exchange forward contracts	Prepaid expenses and other current assets	2	2		2		—		—

			$	3	$	3	$	2	$	2
Liabilities
Commodity purchase futures contracts	Accounts payable and accrued liabilities	1	1		1		—		—
Commodity purchase swaps contracts	Accounts payable and accrued liabilities	2	—		—		1		1

			$	1	$	1	$	1	$	1

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:


			9/30/2023				6/30/2023
	Balance sheet classification	Fair value hierarchy level	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets
Interest-bearing investments, including money market funds	Cash and cash equivalents (1)	1	$	388	$	388	$	243	$	243
Time deposits	Cash and cash equivalents (1)	2	16		16		9		9


Trust assets for nonqualified deferred compensation plans	Other assets	1	137		137		129		129
			$	541	$	541	$	381	$	381
Liabilities
Notes and loans payable	Notes and loans payable (2)	2	$	347	$	347	$	50	$	50

Current maturities of long-term debt and Long-term debt	Current maturities of long- term debt and Long-term debt (3)	2	2,478		2,259		2,477		2,327
			$	2,825	$	2,606	$	2,527	$	2,377

INCOME TAXES	3 Months Ended
INCOME TAXES	Sep. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXESIn determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 14.6% and 25.0% for the three months ended September 30, 2023 and 2022, respectively. The lower tax rate on earnings was primarily driven by the impact of temporary relief provided by the Internal Revenue Service relating to U.S. foreign tax credit regulations.

NET EARNINGS PER SHARE (EPS)

3 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

NET EARNINGS PER SHARE (EPS)

The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:


	Three months ended
	9/30/2023	9/30/2022
Basic	123,973	123,339
Dilutive effect of stock options and other	677	575
Diluted	124,650	123,914

Antidilutive stock options and other	2,220	2,983

Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.

COMPREHENSIVE INCOME

3 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

COMPREHENSIVE INCOME

The following table provides a summary of Comprehensive income for the periods indicated:


	Three months ended
	9/30/2023		9/30/2022
Net earnings	$	25	$	87
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(11)		(29)
Net unrealized gains (losses) on derivatives	(1)		(8)
Pension and postretirement benefit adjustments	11		1
Total other comprehensive (loss) income, net of tax	(1)		(36)
Comprehensive income	24		51
Less: Total comprehensive income attributable to noncontrolling interests	3		2
Total comprehensive income attributable to Clorox	$	21	$	49

STOCKHOLDERS' EQUITY

3 Months Ended

Sep. 30, 2023

Equity [Abstract]

STOCKHOLDERS' EQUITY

STOCKHOLDERS’ EQUITY

Changes in the components of Stockholders’ equity were as follows for the periods indicated:


	Three months ended September 30
(Dollars in millions except per share data; shares in thousands)	Common stock			Additional paid-in capital		Retained earnings		Treasury stock			Accumulated other comprehensive net (loss) income		Noncontrolling interests		Total stockholders’ equity
	Amount		Shares					Amount		Shares
Balance as of June 30, 2022	$	131	130,741	$	1,202	$	1,048	$	(1,346)	(7,589)	$	(479)	$	173	$	729
Net earnings	—		—	—		85		—		—	—		2		87
Other comprehensive (loss) income	—		—	—		—		—		—	(36)		—		(36)
Dividends to Clorox stockholders ($2.36 per share declared)	—		—	—		(293)		—		—	—		—		(293)
Dividends to noncontrolling interests	—		—	—		—		—		—	—		(5)		(5)

Stock-based compensation	—		—	10		—		—		—	—		—		10
Other employee stock plan activities	—		—	(19)		(8)		31		204	—		—		4


Balance as of September 30, 2022	$	131	130,741	$	1,193	$	832	$	(1,315)	(7,385)	$	(515)	$	170	$	496

Balance as of June 30, 2023	$	131	130,741	$	1,245	$	583	$	(1,246)	(6,921)	$	(493)	$	168	$	388
Net earnings (losses)	—		—	—		22		—		—	—		3		25
Other comprehensive (loss) income	—		—	—		—		—		—	(1)		—		(1)
Dividends to Clorox stockholders ($2.40 per share declared)	—		—	—		(300)		—		—	—		—		(300)
Dividends to noncontrolling interests	—		—	—		—		—		—	—		(3)		(3)

Stock-based compensation	—		—	13		—		—		—	—		—		13
Other employee stock plan activities	—		—	(12)		(6)		27		181	—		—		9



Balance as of September 30, 2023	$	131	130,741	$	1,246	$	299	$	(1,219)	(6,740)	$	(494)	$	168	$	131

Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:


	Three months ended September 30
	Foreign currency translation adjustments		Net unrealized gains (losses) on derivatives		Pension and postretirement benefit adjustments		Accumulated other comprehensive net (loss) income
Balance as of June 30, 2022	$	(448)	$	121	$	(152)	$	(479)
Other comprehensive (loss) income before reclassifications	(29)		(2)		—		(31)
Amounts reclassified from Accumulated other comprehensive net (loss) income	—		(8)		1		(7)
Income tax benefit (expense)	—		2		—		2
Net current period other comprehensive (loss) income	(29)		(8)		1		(36)
Balance as of September 30, 2022	$	(477)	$	113	$	(151)	$	(515)

Balance as of June 30, 2023	$	(445)	$	99	$	(147)	$	(493)
Other comprehensive (loss) income before reclassifications	(11)		—		11		—
Amounts reclassified from Accumulated other comprehensive net (loss) income	—		(1)		3		2
Income tax benefit (expense), and other	—		—		(3)		(3)
Net current period other comprehensive (loss) income	(11)		(1)		11		(1)
Balance as of September 30, 2023	$	(456)	$	98	$	(136)	$	(494)

EMPLOYEE BENEFIT PLANS

3 Months Ended

Sep. 30, 2023

Retirement Benefits [Abstract]

EMPLOYEE BENEFIT PLANS

The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:


	Three months ended
	9/30/2023		9/30/2022

Interest cost	$	5	$	5
Expected return on plan assets (1)	(3)		(3)
Settlement loss recognized	1		—
Amortization of unrecognized items	2		2
Total	$	5	$	4

(1)The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2024 net periodic benefit cost is 3.5%.

The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2023 and 2022.

During both the three months ended September 30, 2023 and 2022, the Company made $2 in contributions to its domestic retirement income plans.

Service cost component of the net periodic benefit cost, if any, is reflected in employee benefit costs. All other components are reflected in Other (income) expense, net.

OTHER CONTINGENCIES AND GUARANTEES	3 Months Ended
OTHER CONTINGENCIES AND GUARANTEES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
OTHER CONTINGENCIES AND GUARANTEES	OTHER CONTINGENCIES AND GUARANTEES Contingencies The Company is involved in certain environmental matters, including response actions at various locations. The Company recorded liabilities totaling $28 as of both September 30, 2023 and June 30, 2023, respectively, for its share of aggregate future remediation costs related to these matters. One matter, which accounted for $12 of the recorded liability as of both September 30, 2023 and June 30, 2023, respectively, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing groundwater at the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study related to groundwater. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators. In January 2023, the regulators issued a new order directing the Company and the current property owner to conduct a Remedial Investigation and then prepare a Feasibility Study to evaluate and remediate impacts to soil, soil vapor and indoor air. While the Company believes its latest estimates of remediation costs (including any related to soil, soil vapor and indoor air impacts) are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs in the aggregate of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs. Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability as of both September 30, 2023 and June 30, 2023, respectively. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing agreement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. From time to time, the Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements (including costs connected to the transition and unwinding of certain supply and manufacturing relationships), product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole. Guarantees In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole. The Company had not recorded any material liabilities on the aforementioned guarantees as of both September 30, 2023 and June 30, 2023. The Company was a party to letters of credit of $15 as of September 30, 2023, primarily related to its insurance carriers, of which $0 had been drawn upon.

SEGMENT RESULTS

3 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

SEGMENT RESULTS


	Net sales
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	504	$	657
Household	325		423
Lifestyle	229		320
International	270		285
Corporate and Other	58		55

Total	$	1,386	$	1,740

	Segment adjusted EBIT
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	104	$	133
Household	(4)		22
Lifestyle	19		60
International	34		23
Corporate and Other	(62)		(63)
Total	$	91	$	175
Interest income	10		2
Interest expense	(21)		(22)

Cyberattack costs (1)	(24)		—
Streamlined operating model (2)	—		(19)
Digital capabilities and productivity enhancements investment (3)	(27)		(20)
Earnings before income taxes	$	29	$	116


	Three months ended
	9/30/2023
Health and Wellness	22	%
Household	11
Lifestyle	14
International	1
Corporate and Other	52
Total	100	%


	Three months ended		Three months ended		Inception to date ended
	9/30/2023		9/30/2022		9/30/2023
Health and Wellness	—	%	6	%	6	%
Household	—		—		1
Lifestyle	—		5		3
International	—		19		16
Corporate and Other	—		70		74
Total	—	%	100	%	100	%

(3)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.

All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.

Net sales to the Company’s largest customer, Walmart Inc. and its affiliates, as a percentage of consolidated net sales, were 27% for both the three months ended September 30, 2023 and 2022.

The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the periods indicated:


	Net sales
	Three months ended
	9/30/2023		9/30/2022
Cleaning	32	%	33	%
Professional Products	4		5

Health and Wellness	36	%	38	%
Bags and Wraps	11		11
Cat Litter	8		8
Grilling	5		5
Household	24	%	24	%
Food	9		10
Natural Personal Care	3		4
Water Filtration	5		5
Lifestyle	17	%	19	%
International	19	%	16	%
Corporate and Other	4	%	3	%
Total	100	%	100	%

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 22	$ 85

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2023 and 2022, in the opinion of management, reflect all normal and recurring adjustments considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company or Clorox) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2023, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-04, "Liabilities - Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations.” These amendments require disclosure of the key terms of outstanding supplier finance programs and a rollforward of the related obligations. These amendments are effective for fiscal years beginning after December 15, 2022, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted the standard as of July 1, 2023. The adoption relates to disclosures only and does not have an impact on the condensed consolidated financial statements, results of operations, or cash flows.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. As of both September 30, 2023 and June 30, 2023, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis during the period included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
Segment Results	The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. Operating segments not aggregated into a reportable segment are reflected in Corporate and Other. Corporate and Other includes certain non-allocated administrative costs and various other non-operating income and expenses, as well as the results of the Vitamins, Minerals and Supplements (VMS) business. Assets in Corporate and Other include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes, as well as the assets related to the VMS business.

CYBERATTACK (Tables)

3 Months Ended

Sep. 30, 2023

Unusual or Infrequent Items, or Both [Abstract]

Summary of Costs Recognized From Cyberattack

The following table summarizes the recognition of costs in the condensed consolidated statement of earnings and comprehensive income:


	Three months ended
	9/30/2023
Costs of products sold	$	11
Selling and administrative expenses	13
Total	$	24

RESTRUCTURING AND RELATED COSTS (Tables)

3 Months Ended

Sep. 30, 2023

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs


	Three months ended				Inception to date ended
	9/30/2023		9/30/2022			9/30/2023
Costs of products sold	$	—	$	(1)		$	(3)
Selling and administrative expenses	—		1			12
Research and development	—		—			(1)
Other (income) expense, net:
Employee-related costs	—		19			52


Total, net	$	—	$	19		$	60

Schedule of Restructuring Reserve by Type of Cost


	Employee-Related Costs		Other		Total
Accrual Balance as of June 30, 2023	$	23	$	5	$	28
Charges	—		—		—
Cash payments	(16)		(5)		(21)

Accrual Balance as of September 30, 2023	$	7	$	—	$	7

INVENTORIES, NET (Tables)

3 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventories, Net

Inventories, net consisted of the following as of:


	9/30/2023		6/30/2023
Finished goods	$	618	$	595
Raw materials and packaging	178		182
Work in process	20		8
LIFO allowances	(104)		(87)
Total inventories, net	$	712	$	698
Less: Non-current inventories, net (1)	2		2
Total current inventories, net	$	710	$	696

(1)Non-current inventories, net are recorded in Other assets.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Sep. 30, 2023

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]

Effects of Derivative Instruments Designated as Hedging Instruments on OCI

The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:


	Gains (losses) recognized in Other comprehensive (loss) income
	Three months ended
	9/30/2023		9/30/2022
Commodity purchase derivative contracts	$	(1)	$	(3)
Foreign exchange derivative contracts	1		1
Interest rate derivative contracts	—		—
Total	$	—	$	(2)

Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings


	Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings	Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
		Three months ended
		9/30/2023		9/30/2022
Commodity purchase derivative contracts	Cost of products sold	$	(2)	$	4
Foreign exchange derivative contracts	Cost of products sold	—		1
Interest rate derivative contracts	Interest expense	3		3
Total		$	1	$	8

Schedule of Assets and Liabilities for Fair Value Disclosure

The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:


			9/30/2023				6/30/2023
	Balance sheet classification	Fair value hierarchy level	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets
Commodity purchase options contracts	Prepaid expenses and other current assets	1	$	—	$	—	$	2	$	2
Commodity purchase swaps contracts	Prepaid expenses and other current assets	2	1		1		—		—

Foreign exchange forward contracts	Prepaid expenses and other current assets	2	2		2		—		—

			$	3	$	3	$	2	$	2
Liabilities
Commodity purchase futures contracts	Accounts payable and accrued liabilities	1	1		1		—		—
Commodity purchase swaps contracts	Accounts payable and accrued liabilities	2	—		—		1		1

			$	1	$	1	$	1	$	1

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:


			9/30/2023				6/30/2023
	Balance sheet classification	Fair value hierarchy level	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets
Interest-bearing investments, including money market funds	Cash and cash equivalents (1)	1	$	388	$	388	$	243	$	243
Time deposits	Cash and cash equivalents (1)	2	16		16		9		9


Trust assets for nonqualified deferred compensation plans	Other assets	1	137		137		129		129
			$	541	$	541	$	381	$	381
Liabilities
Notes and loans payable	Notes and loans payable (2)	2	$	347	$	347	$	50	$	50

Current maturities of long-term debt and Long-term debt	Current maturities of long- term debt and Long-term debt (3)	2	2,478		2,259		2,477		2,327
			$	2,825	$	2,606	$	2,527	$	2,377

NET EARNINGS PER SHARE (EPS) (Tables)

3 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares

The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:


	Three months ended
	9/30/2023	9/30/2022
Basic	123,973	123,339
Dilutive effect of stock options and other	677	575
Diluted	124,650	123,914

Antidilutive stock options and other	2,220	2,983

COMPREHENSIVE INCOME (Tables)

3 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Schedule of Comprehensive Income

The following table provides a summary of Comprehensive income for the periods indicated:


	Three months ended
	9/30/2023		9/30/2022
Net earnings	$	25	$	87
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(11)		(29)
Net unrealized gains (losses) on derivatives	(1)		(8)
Pension and postretirement benefit adjustments	11		1
Total other comprehensive (loss) income, net of tax	(1)		(36)
Comprehensive income	24		51
Less: Total comprehensive income attributable to noncontrolling interests	3		2
Total comprehensive income attributable to Clorox	$	21	$	49

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of Stockholders Equity

Changes in the components of Stockholders’ equity were as follows for the periods indicated:


	Three months ended September 30
(Dollars in millions except per share data; shares in thousands)	Common stock			Additional paid-in capital		Retained earnings		Treasury stock			Accumulated other comprehensive net (loss) income		Noncontrolling interests		Total stockholders’ equity
	Amount		Shares					Amount		Shares
Balance as of June 30, 2022	$	131	130,741	$	1,202	$	1,048	$	(1,346)	(7,589)	$	(479)	$	173	$	729
Net earnings	—		—	—		85		—		—	—		2		87
Other comprehensive (loss) income	—		—	—		—		—		—	(36)		—		(36)
Dividends to Clorox stockholders ($2.36 per share declared)	—		—	—		(293)		—		—	—		—		(293)
Dividends to noncontrolling interests	—		—	—		—		—		—	—		(5)		(5)

Stock-based compensation	—		—	10		—		—		—	—		—		10
Other employee stock plan activities	—		—	(19)		(8)		31		204	—		—		4


Balance as of September 30, 2022	$	131	130,741	$	1,193	$	832	$	(1,315)	(7,385)	$	(515)	$	170	$	496

Balance as of June 30, 2023	$	131	130,741	$	1,245	$	583	$	(1,246)	(6,921)	$	(493)	$	168	$	388
Net earnings (losses)	—		—	—		22		—		—	—		3		25
Other comprehensive (loss) income	—		—	—		—		—		—	(1)		—		(1)
Dividends to Clorox stockholders ($2.40 per share declared)	—		—	—		(300)		—		—	—		—		(300)
Dividends to noncontrolling interests	—		—	—		—		—		—	—		(3)		(3)

Stock-based compensation	—		—	13		—		—		—	—		—		13
Other employee stock plan activities	—		—	(12)		(6)		27		181	—		—		9



Balance as of September 30, 2023	$	131	130,741	$	1,246	$	299	$	(1,219)	(6,740)	$	(494)	$	168	$	131

Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income

Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:


	Three months ended September 30
	Foreign currency translation adjustments		Net unrealized gains (losses) on derivatives		Pension and postretirement benefit adjustments		Accumulated other comprehensive net (loss) income
Balance as of June 30, 2022	$	(448)	$	121	$	(152)	$	(479)
Other comprehensive (loss) income before reclassifications	(29)		(2)		—		(31)
Amounts reclassified from Accumulated other comprehensive net (loss) income	—		(8)		1		(7)
Income tax benefit (expense)	—		2		—		2
Net current period other comprehensive (loss) income	(29)		(8)		1		(36)
Balance as of September 30, 2022	$	(477)	$	113	$	(151)	$	(515)

Balance as of June 30, 2023	$	(445)	$	99	$	(147)	$	(493)
Other comprehensive (loss) income before reclassifications	(11)		—		11		—
Amounts reclassified from Accumulated other comprehensive net (loss) income	—		(1)		3		2
Income tax benefit (expense), and other	—		—		(3)		(3)
Net current period other comprehensive (loss) income	(11)		(1)		11		(1)
Balance as of September 30, 2023	$	(456)	$	98	$	(136)	$	(494)

EMPLOYEE BENEFIT PLANS (Tables)

3 Months Ended

Sep. 30, 2023

Retirement Benefits [Abstract]

Schedule of Components of Net Periodic Benefit Cost

The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:


	Three months ended
	9/30/2023		9/30/2022

Interest cost	$	5	$	5
Expected return on plan assets (1)	(3)		(3)
Settlement loss recognized	1		—
Amortization of unrecognized items	2		2
Total	$	5	$	4

(1)The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2024 net periodic benefit cost is 3.5%.

SEGMENT RESULTS (Tables)

3 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Selected Financial Information Relating to the Company's Segments


	Net sales
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	504	$	657
Household	325		423
Lifestyle	229		320
International	270		285
Corporate and Other	58		55

Total	$	1,386	$	1,740

	Segment adjusted EBIT
	Three months ended
	9/30/2023		9/30/2022
Health and Wellness	$	104	$	133
Household	(4)		22
Lifestyle	19		60
International	34		23
Corporate and Other	(62)		(63)
Total	$	91	$	175
Interest income	10		2
Interest expense	(21)		(22)

Cyberattack costs (1)	(24)		—
Streamlined operating model (2)	—		(19)
Digital capabilities and productivity enhancements investment (3)	(27)		(20)
Earnings before income taxes	$	29	$	116


	Three months ended
	9/30/2023
Health and Wellness	22	%
Household	11
Lifestyle	14
International	1
Corporate and Other	52
Total	100	%


	Three months ended		Three months ended		Inception to date ended
	9/30/2023		9/30/2022		9/30/2023
Health and Wellness	—	%	6	%	6	%
Household	—		—		1
Lifestyle	—		5		3
International	—		19		16
Corporate and Other	—		70		74
Total	—	%	100	%	100	%

(3)Represents expenses related to the Company’s digital capabilities and productivity enhancements investment corresponding to Corporate and Other.

The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by operating segment, for the periods indicated:


	Net sales
	Three months ended
	9/30/2023		9/30/2022
Cleaning	32	%	33	%
Professional Products	4		5

Health and Wellness	36	%	38	%
Bags and Wraps	11		11
Cat Litter	8		8
Grilling	5		5
Household	24	%	24	%
Food	9		10
Natural Personal Care	3		4
Water Filtration	5		5
Lifestyle	17	%	19	%
International	19	%	16	%
Corporate and Other	4	%	3	%
Total	100	%	100	%

CYBERATTACK (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
CYBERATTACK (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022
Unusual or Infrequent Item, or Both [Line Items]
Incremental expenses	$ 24	$ 0
Cyberattack
Unusual or Infrequent Item, or Both [Line Items]
Incremental expenses	24
Insurance proceeds	$ 0

CYBERATTACK (Summary of Costs Recognized From Cyberattack) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Unusual or Infrequent Item, or Both [Line Items]
Total	$ 24	$ 0
Cyberattack
Unusual or Infrequent Item, or Both [Line Items]
Total	24
Cyberattack \| Costs of products sold
Unusual or Infrequent Item, or Both [Line Items]
Total	11
Cyberattack \| Selling and administrative expenses
Unusual or Infrequent Item, or Both [Line Items]
Total	$ 13

SUPPLY CHAIN FINANCING PROGRAM (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Supplier Finance Program [Line Items]
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable and accrued liabilities	Accounts payable and accrued liabilities
Amount due to suppliers participating in SCF	$ 119	$ 220
Maximum
Supplier Finance Program [Line Items]
SCF payment term	120 days

RESTRUCTURING AND RELATED COSTS (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended	15 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring and related implementation, incurred cost	$ 0	$ 19	$ 60	$ 60
Minimum \| Forecast
Restructuring Cost and Reserve [Line Items]
Restructuring and related implementation, expected cost					$ 30
Minimum \| Forecast \| Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related implementation, expected cost					10
Maximum \| Forecast
Restructuring Cost and Reserve [Line Items]
Restructuring and related implementation, expected cost					40
Maximum \| Forecast \| Employee-Related Costs
Restructuring Cost and Reserve [Line Items]
Restructuring and related implementation, expected cost					$ 15

RESTRUCTURING AND RELATED COSTS (Restructuring and Related Costs) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended	15 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023
Restructuring Cost and Reserve [Line Items]
Total, net	$ 0	$ 19	$ 60	$ 60
Costs of products sold
Restructuring Cost and Reserve [Line Items]
Total, net	$ 0	$ (1)		$ (3)
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold	Cost of products sold		Cost of products sold
Selling and administrative expenses
Restructuring Cost and Reserve [Line Items]
Total, net	$ 0	$ 1		$ 12
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling and administrative expenses	Selling and administrative expenses		Selling and administrative expenses
Research and development
Restructuring Cost and Reserve [Line Items]
Total, net	$ 0	$ 0		$ (1)
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Research and development costs	Research and development costs		Research and development costs
Other (income) expense, net
Restructuring Cost and Reserve [Line Items]
Total, net	$ 0	$ 19		$ 52
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other (income) expense, net	Other (income) expense, net		Other (income) expense, net

RESTRUCTURING AND RELATED COSTS (Accrual Reconciliation) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Beginning accrual balance	$ 28
Charges	0
Cash payments	(21)
Ending accrual balance	7
Employee-Related Costs
Restructuring Reserve [Roll Forward]
Beginning accrual balance	23
Charges	0
Cash payments	(16)
Ending accrual balance	7
Other
Restructuring Reserve [Roll Forward]
Beginning accrual balance	5
Charges	0
Cash payments	(5)
Ending accrual balance	$ 0

INVENTORIES, NET (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Inventory Disclosure [Abstract]
Finished goods	$ 618	$ 595
Raw materials and packaging	178	182
Work in process	20	8
LIFO allowances	(104)	(87)
Total inventories, net	712	698
Less: Non-current inventories, net	2	2
Total current inventories, net	$ 710	$ 696

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023
Derivative [Line Items]
Maximum duration, foreign exchange contracts (in years)	2 years
Maximum duration, interest rate contracts (in years)	3 years
Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months	$ 13
Amount of derivative instruments subject to contractually defined counterparty liability position limits	0	$ 1
Commodity purchase derivative contracts
Derivative [Line Items]
Cash margin balances amount	2	0
Purchases of Inventory \| Foreign exchange derivative contracts
Derivative [Line Items]
Notional amount	$ 55	51
Total Commodity Purchase Derivative Contracts
Derivative [Line Items]
Maximum duration, commodity contracts (in years)	2 years
Notional amount	$ 36	$ 41

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in Other comprehensive (loss) income	$ 0	$ (2)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings	1	8
Commodity purchase derivative contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in Other comprehensive (loss) income	(1)	(3)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings	(2)	4
Foreign exchange derivative contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in Other comprehensive (loss) income	1	1
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings	0	1
Interest rate derivative contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gains (losses) recognized in Other comprehensive (loss) income	0	0
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings	$ 3	$ 3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Values of Derivative Instruments) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 3	$ 2
Liabilities	1	1
Estimated Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	3	2
Liabilities	1	1
Commodity purchase options contracts \| Fair Value, Inputs, Level 1 \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	2
Liabilities	1	0
Commodity purchase options contracts \| Fair Value, Inputs, Level 1 \| Estimated Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	2
Liabilities	1	0
Commodity purchase options contracts \| Fair Value, Inputs, Level 2 \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1	0
Liabilities	0	1
Commodity purchase options contracts \| Fair Value, Inputs, Level 2 \| Estimated Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1	0
Liabilities	0	1
Foreign exchange forward contracts \| Fair Value, Inputs, Level 2 \| Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	2	0
Foreign exchange forward contracts \| Fair Value, Inputs, Level 2 \| Estimated Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 2	$ 0

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jun. 30, 2023
Assets
Cash and cash equivalents	$ 518	$ 367
Total assets	5,991	5,945
Liabilities
Notes and loans payable	347	50
Total liabilities	5,860	5,557
Carrying Amount
Assets
Total assets	541	381
Liabilities
Total liabilities	2,825	2,527
Estimated Fair Value
Assets
Total assets, estimated fair value	541	381
Liabilities
Total liabilities, estimated fair value	2,606	2,377
Fair Value, Inputs, Level 1 \| Carrying Amount \| Trust assets for nonqualified deferred compensation plans
Assets
Trust assets for nonqualified deferred compensation plans	137	129
Fair Value, Inputs, Level 1 \| Estimated Fair Value \| Trust assets for nonqualified deferred compensation plans
Assets
Trust assets for nonqualified deferred compensation plans, estimated fair value	137	129
Fair Value, Inputs, Level 2 \| Carrying Amount \| Current maturities of long-term debt and Long-term debt
Liabilities
Current maturities of long-term debt and Long-term debt	2,478	2,477
Fair Value, Inputs, Level 2 \| Carrying Amount \| Notes and loans payable
Liabilities
Notes and loans payable	347	50
Fair Value, Inputs, Level 2 \| Estimated Fair Value \| Current maturities of long-term debt and Long-term debt
Liabilities
Current maturities of long-term debt and Long-term debt, estimated fair value	2,259	2,327
Fair Value, Inputs, Level 2 \| Estimated Fair Value \| Notes and loans payable
Liabilities
Notes and loans payable, estimated fair value	347	50
Interest-bearing investments, including money market funds \| Fair Value, Inputs, Level 1 \| Carrying Amount
Assets
Cash and cash equivalents	388	243
Interest-bearing investments, including money market funds \| Fair Value, Inputs, Level 1 \| Estimated Fair Value
Assets
Cash and cash equivalents, estimated fair value	388	243
Time deposits \| Fair Value, Inputs, Level 2 \| Carrying Amount
Assets
Cash and cash equivalents	16	9
Time deposits \| Fair Value, Inputs, Level 2 \| Estimated Fair Value
Assets
Cash and cash equivalents, estimated fair value	$ 16	$ 9

INCOME TAXES (Details)	3 Months Ended
INCOME TAXES (Details)	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective tax rate on earnings from continuing operations	14.60%	25.00%

NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares) (Details) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Basic (in shares)	123,973	123,339
Dilutive effect of stock options and other (in shares)	677	575
Diluted (in shares)	124,650	123,914
Antidilutive stock options and other (in shares)	2,220	2,983

COMPREHENSIVE INCOME (Details) - USD ($) $ in Millions	3 Months Ended
COMPREHENSIVE INCOME (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Net earnings	$ 25	$ 87
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(11)	(29)
Net unrealized gains (losses) on derivatives	(1)	(8)
Pension and postretirement benefit adjustments	11	1
Total other comprehensive (loss) income, net of tax	(1)	(36)
Comprehensive income	24	51
Less: Total comprehensive income attributable to noncontrolling interests	3	2
Total comprehensive income attributable to Clorox	$ 21	$ 49

STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 388	$ 729
Beginning balance, common stock (in shares)	123,820,022
Beginning balance, treasury stock (in shares)	(6,921,439)
Net earnings (losses)	$ 25	87
Other comprehensive (loss) income	(1)	(36)
Dividends to Clorox stockholders	(300)	(293)
Dividends to noncontrolling interests	(3)	(5)
Stock-based compensation	13	10
Other employee stock plan activities	9	4
Ending balance	$ 131	$ 496
Ending balance, common stock (in shares)	124,001,348
Ending balance, treasury stock (in shares)	(6,740,113)
Dividends declared per share (in dollars per share)	$ 2.40	$ 2.36
Common stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 131	$ 131
Beginning balance, common stock (in shares)	130,741,000	130,741,000
Ending balance	$ 131	$ 131
Ending balance, common stock (in shares)	130,741,000	130,741,000
Additional paid-in capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 1,245	$ 1,202
Stock-based compensation	13	10
Other employee stock plan activities	(12)	(19)
Ending balance	1,246	1,193
Retained earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	583	1,048
Net earnings (losses)	22	85
Dividends to Clorox stockholders	(300)	(293)
Other employee stock plan activities	(6)	(8)
Ending balance	299	832
Treasury stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ (1,246)	$ (1,346)
Beginning balance, treasury stock (in shares)	(6,921,000)	(7,589,000)
Other employee stock plan activities	$ 27	$ 31
Other employee stock plan activities (in shares)	181,000	204,000
Ending balance	$ (1,219)	$ (1,315)
Ending balance, treasury stock (in shares)	(6,740,000)	(7,385,000)
Accumulated other comprehensive net (loss) income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ (493)	$ (479)
Other comprehensive (loss) income	(1)	(36)
Ending balance	(494)	(515)
Noncontrolling interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	168	173
Net earnings (losses)	3	2
Dividends to noncontrolling interests	(3)	(5)
Ending balance	$ 168	$ 170

STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses)) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning	$ 220
Total other comprehensive (loss) income, net of tax	(1)	$ (36)
Balance, ending	(37)
Accumulated other comprehensive net (loss) income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning	(493)	(479)
Other comprehensive (loss) income before reclassifications	0	(31)
Amounts reclassified from Accumulated other comprehensive net (loss) income	2	(7)
Income tax benefit (expense), and other	(3)	2
Total other comprehensive (loss) income, net of tax	(1)	(36)
Balance, ending	(494)	(515)
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning	(445)	(448)
Other comprehensive (loss) income before reclassifications	(11)	(29)
Amounts reclassified from Accumulated other comprehensive net (loss) income	0	0
Income tax benefit (expense), and other	0	0
Total other comprehensive (loss) income, net of tax	(11)	(29)
Balance, ending	(456)	(477)
Net unrealized gains (losses) on derivatives
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning	99	121
Other comprehensive (loss) income before reclassifications	0	(2)
Amounts reclassified from Accumulated other comprehensive net (loss) income	(1)	(8)
Income tax benefit (expense), and other	0	2
Total other comprehensive (loss) income, net of tax	(1)	(8)
Balance, ending	98	113
Pension and postretirement benefit adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning	(147)	(152)
Other comprehensive (loss) income before reclassifications	11	0
Amounts reclassified from Accumulated other comprehensive net (loss) income	3	1
Income tax benefit (expense), and other	(3)	0
Total other comprehensive (loss) income, net of tax	11	1
Balance, ending	$ (136)	$ (151)

EMPLOYEE BENEFIT PLANS (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Other Postretirement Benefits Plan \| Retirement Income Plans \| UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Discount rate used for benefit obligation remeasurement		5.00%
Net unrealized loss in AOCI, net of tax		$ 126
Net unrealized loss in AOCI, before taxes		165
Net periodic benefit cost		5	$ 4
Retirement plan contributions		2	2
Other Postretirement Benefits Plan \| Retirement Income Plans \| UNITED STATES \| Forecast
Defined Benefit Plan Disclosure [Line Items]
One-time non-cash before tax settlement charge	$ 165
Postretirement Health Coverage \| Retirement Health Care
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost		$ 0	$ 0

EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income) (Details) - Other Postretirement Benefits Plan - Retirement Income Plans - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Settlement loss recognized	$ 1	$ 0
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Interest cost	5	5
Expected return on plan assets	(3)	(3)
Amortization of unrecognized items	2	2
Total	$ 5	$ 4
Weighted average long-term expected rate or return on plan assets (percentage)	3.50%

OTHER CONTINGENCIES AND GUARANTEES (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023
Loss Contingencies [Line Items]
Liability for aggregate future remediation costs	$ 28	$ 28
Letter of credit	15
Letter of credit, amount outstanding	0
Alameda County, California Matter
Loss Contingencies [Line Items]
Liability for aggregate future remediation costs	$ 12	12
Remediation period (in years)	30 years
Maximum undiscounted costs	$ 28
Dickinson County, Michigan Matter
Loss Contingencies [Line Items]
Liability for aggregate future remediation costs	$ 10	$ 10
Remediation period (in years)	30 years
Percentage of liability for aggregate remediation and associated costs, other than legal fees	24.30%

SEGMENT RESULTS (Narrative) (Details) - reportableSegment	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Concentration Risk [Line Items]
Number of reportable segments	4
Revenue from Contract with Customer \| Customer Concentration Risk \| Walmart Stores, Inc.
Concentration Risk [Line Items]
Concentration percentage	27.00%	27.00%

SEGMENT RESULTS (Reportable Segment Information ) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended	15 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023
Segment Reporting Information [Line Items]
Net sales	$ 1,386	$ 1,740
Interest income	10	2
Interest expense	(21)	(22)
Cyberattack costs	(24)	0
Streamlined operating model	0	(19)	$ (60)	$ (60)
Digital capabilities and productivity enhancements investment	(27)	(20)
Earnings before income taxes	$ 29	$ 116
Cyberattack \| Product Concentration Risk
Segment Reporting Information [Line Items]
Concentration percentage	100.00%
Restructuring and Related Costs \| Product Concentration Risk \| Employee-Related Costs
Segment Reporting Information [Line Items]
Concentration percentage	0.00%	100.00%		100.00%
Operating Segments \| Health and Wellness
Segment Reporting Information [Line Items]
Net sales	$ 504	$ 657
Segment adjusted EBIT	$ 104	$ 133
Operating Segments \| Health and Wellness \| Cyberattack \| Product Concentration Risk
Segment Reporting Information [Line Items]
Concentration percentage	22.00%
Operating Segments \| Health and Wellness \| Restructuring and Related Costs \| Product Concentration Risk \| Employee-Related Costs
Segment Reporting Information [Line Items]
Concentration percentage	0.00%	6.00%		6.00%
Operating Segments \| Household
Segment Reporting Information [Line Items]
Net sales	$ 325	$ 423
Segment adjusted EBIT	$ (4)	$ 22
Operating Segments \| Household \| Cyberattack \| Product Concentration Risk
Segment Reporting Information [Line Items]
Concentration percentage	11.00%
Operating Segments \| Household \| Restructuring and Related Costs \| Product Concentration Risk \| Employee-Related Costs
Segment Reporting Information [Line Items]
Concentration percentage	0.00%	0.00%		1.00%
Operating Segments \| Lifestyle
Segment Reporting Information [Line Items]
Net sales	$ 229	$ 320
Segment adjusted EBIT	$ 19	$ 60
Operating Segments \| Lifestyle \| Cyberattack \| Product Concentration Risk
Segment Reporting Information [Line Items]
Concentration percentage	14.00%
Operating Segments \| Lifestyle \| Restructuring and Related Costs \| Product Concentration Risk \| Employee-Related Costs
Segment Reporting Information [Line Items]
Concentration percentage	0.00%	5.00%		3.00%
Operating Segments \| International
Segment Reporting Information [Line Items]
Net sales	$ 270	$ 285
Segment adjusted EBIT	$ 34	$ 23
Operating Segments \| International \| Cyberattack \| Product Concentration Risk
Segment Reporting Information [Line Items]
Concentration percentage	1.00%
Operating Segments \| International \| Restructuring and Related Costs \| Product Concentration Risk \| Employee-Related Costs
Segment Reporting Information [Line Items]
Concentration percentage	0.00%	19.00%		16.00%
Corporate and Other
Segment Reporting Information [Line Items]
Net sales	$ 58	$ 55
Segment adjusted EBIT	$ (62)	$ (63)
Corporate and Other \| Cyberattack \| Product Concentration Risk
Segment Reporting Information [Line Items]
Concentration percentage	52.00%
Corporate and Other \| Restructuring and Related Costs \| Product Concentration Risk \| Employee-Related Costs
Segment Reporting Information [Line Items]
Concentration percentage	0.00%	70.00%		74.00%
Operating Segments and Corporate, Non-Segment
Segment Reporting Information [Line Items]
Segment adjusted EBIT	$ 91	$ 175

SEGMENT RESULTS (Net Sales Percentages) (Details) - Revenue from Contract with Customer - Product Concentration Risk	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Concentration percentage	100.00%	100.00%
Corporate and Other
Segment Reporting Information [Line Items]
Concentration percentage	4.00%	3.00%
Health and Wellness \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	36.00%	38.00%
Health and Wellness \| Cleaning \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	32.00%	33.00%
Health and Wellness \| Professional Products \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	4.00%	5.00%
Household \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	24.00%	24.00%
Household \| Bags and Wraps \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	11.00%	11.00%
Household \| Cat Litter \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	8.00%	8.00%
Household \| Grilling \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	5.00%	5.00%
Lifestyle \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	17.00%	19.00%
Lifestyle \| Food \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	9.00%	10.00%
Lifestyle \| Natural Personal Care \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	3.00%	4.00%
Lifestyle \| Water Filtration \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	5.00%	5.00%
International \| Operating Segments
Segment Reporting Information [Line Items]
Concentration percentage	19.00%	16.00%